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Clinical applications of tissue engineering are constrained by the ability 
of the implanted construct to invoke vascularization in adequate extent 
and velocity. To overcome the current limitations presented by local 
delivery of single angiogenic factors, we explored the incorporation of 
prolyl hydroxylase inhibitors (PHIs) into scaffolds as an alternative 
vascularization strategy. PHIs are small molecule drugs which can 
stabilize the alpha subunit of hypoxia-inducible factor 1 (HIF-1), a key 
transcription factor that regulates a variety of angiogenic mechanisms, 
via the inhibition of a family of HIF-regulating enzymes known as the 
HIF prolyl hydroxylases (HIF-PHDs). 
In this project, we conjugated the PHI pyridine-2,4-dicarboxylic acid 
(PDCA) via amide bonds to a gelatin sponge (Gelfoam®). Fibroblasts 
cultured on PDCA-Gelfoam were able to infiltrate and proliferate in 
these scaffolds while secreting significantly more vascular endothelial 
growth factor (VEGF) than cells grown on Gelfoam without PDCA. 
Reporter cells expressing GFP-tagged HIF-1α exhibited dose-
dependent stabilization of this angiogenic transcription factor when 
growing within PDCA-Gelfoam constructs. Subsequently, we implanted 
PDCA-Gelfoam scaffolds into the peri-renal fat tissue of Sprague 
Dawley rats for 8 days. Immunostaining of explants revealed that the 
PDCA-Gelfoam scaffolds were amply infiltrated by cells and promoted 
vascular ingrowth in a dose-dependent manner. Thus, the 
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incorporation of PHIs into scaffolds appears to be a feasible strategy 
for improving vascularization in regenerative medicine applications.  
Aside from promoting angiogenesis, PHIs can also exert a range of 
other effects on cells and tissues. As HIF-1 has been shown to be 
involved in bone development, PHIs’ applications in bone regeneration 
are of particular interest. However, PHIs also inhibit collagen prolyl 4-
hydroxylase (P4H), and can thus suppress the production of collagen, 
an important component of bone. Therefore, PHIs’ effects on bone are 
complex. 
To explore PHIs’ effects on bone, we performed a preliminary study to 
investigate PHIs’ effects on several aspects of osteoblast behaviour in 
vitro, by treating osteoblasts with the PHIs PDCA, ciclopirox olamine 
(CPX), and desferrioxamine (DFO). Our results showed that all the 
tested PHIs could stabilize HIF-1α, upregulate VEGF secretion, and 
downregulate collagen secretion and deposition. However, our results 
also revealed that different PHIs can have varied effects on osteoblast 
viability and mineralization, likely due to their different mechanisms of 
action and ranges of inhibitory targets. We also showed that the 
duration of PHI treatment has an influence on resultant osteoblast 
behavior. Taken together, our results suggest that a short initial 
treatment with non-iron chelator PHIs may be preferable in bone 
applications, although in vivo testing in suitable animal models of bone 
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1.1.1. Regenerative medicine – a new paradigm in healthcare 
Advances in healthcare and hygiene have dramatically increased life 
expectancy in the past century, especially in industrialized nations. [1] 
Unlike in the early 1900s, when infectious diseases such as pneumonia, 
tuberculosis, and typhoid had been the leading causes of death even in 
the most developed regions, there are now far fewer people dying 
young from such infections. [2] Instead, chronic diseases such as heart 
disease, stroke, diabetes, and cancer are now the leading causes of 
mortality in the world, representing approximately 60% of all deaths. [3] 
Many of these chronic conditions involve the failure or degeneration of 
organs, for which there is no cure other than organ replacement. In 
addition, cancer and traumatic injuries may necessitate the removal of 
tissues and organs, which again require replacements. 
Traditionally, tissue and organ replacements are performed by 
transplantation or grafting. These can be autologous (i.e. from the 
patient himself), allogeneic (i.e. from other people), or even xenogeneic 
(i.e. from animals). However, autologous transplantations are limited by 
tissue availability and donor site morbidity, while allogeneic and 
xenogeneic transplants have problems of immunogenicity and risks of 
disease transmission. [4, 5] In addition, the demand for allogeneic 
transplants greatly exceeds the supply, leading to long transplant 
waiting lists in many countries. [6] For example, in the United States, 
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28,952 people received transplants in 2013, while 121,970 people 
remained on the waiting list. [7] There is thus a clear need for 
alternatives. 
One such alternative is artificial prostheses, and indeed, many devices 
have been developed to replace mechanical parts of the body, such as 
hip and knee prostheses, prosthetic heart valves, and more recently, 
even an artificial heart, which was first implanted in a patient in 2013. [8, 
9] However, as these prostheses are purely mechanical, they cannot 
perform many important cell-based functions of tissues and organs, 
such as self-renewal and repair, hormone production, and metabolism. 
Therefore, tissues and organs that perform important non-mechanical 
functions cannot be replaced by such prostheses. 
Over the past two decades, a new field has emerged in the quest for 
bioactive artificial tissue and organ replacements. This is the field of 
tissue engineering, which has been defined as "an interdisciplinary field 
that applies the principles of engineering and the life sciences toward 
the development of biological substitutes that restore, maintain, or 
improve tissue function". [10] This definition is traditionally embodied by 
an engineered tissue consisting of cells growing on a biomaterial 




Fig. 1.1. Diagram illustrating the traditional embodiment of “tissue engineering”, in 
which tissue replacements are made by culturing cells on a biodegradable polymer 
scaffold. (Reprinted from [10] with permission. Copyright © 1993 American 
Association for the Advancement of Science.) 
In recent years, it has become apparent that engineered tissues 
constitute only a subset of possible approaches that can “restore, 
maintain, or improve tissue function”. The field has thus been 
expanded to encompass these other approaches, which include gene 
therapy, stem cell transplantation, reprogramming of cells and tissues, 
and the delivery of soluble factors. [11] This broader field is termed 
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“regenerative medicine”, and is unified by the common aim to “replace 
or regenerate human cells, tissue or organs”, in order to “restore or 
establish normal function". [12] These different approaches can be 
used individually, but are often combined to improve efficacy (e.g. 
drug-delivering scaffold seeded with stem cells).  
In the context of this thesis, the term “regenerative medicine” refers to 
therapeutic approaches that aim at regenerating human cells, tissues, 
and organs and restoring their function, while the term “tissue 
engineering” refers to the subset of regenerative medicine approaches 
that involve the design of tissue substitutes. These tissue substitutes, 
henceforth referred to as “engineered tissues”, can take many forms, 
such as a resorbable scaffold which has been pre-seeded with cells, or 
an acellular scaffold which is implanted and subsequently infiltrated by 
cells from the surrounding tissues. In both cases, the implanted 
scaffold eventually degrades, leaving behind newly formed tissue that 
is integrated with the surrounding tissues, and which replaces the 
original missing tissue. This is in contrast to prosthetic devices, which 
are designed to maintain their mechanical integrity during their 
intended duration of function and are not intended to encourage tissue 
growth. 
“Engineered tissues” are thus designed to integrate with the 
surrounding tissues after implantation and encourage regeneration of 
new tissue. Ideally, the implanted biomaterial would eventually be 
resorbed completely, leaving behind a newly-regenerated engineered 
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tissue that is morphologically and functionally indistinguishable from 
the original tissue that it was designed to replace. However, in reality, 
there are a number of obstacles preventing the realization of this goal. 
1.1.2. Vascularization is a major obstacle in tissue engineering 
While the field of tissue engineering has come a long way since its 
original conception in the late 1980s, its clinical applications remain 
limited mainly to thin or avascular tissues, such as skin, cartilage, and 
the cornea, due to difficulties in inducing adequate vascularization. [13-
16] As mammalian cells require oxygen and nutrients for survival, and 
the diffusion limit of oxygen in tissues is only 100 to 200 µm, tissues 
beyond this thickness require a network of blood vessels for adequate 
delivery of oxygen and nutrients. [16, 17] Vascularization is therefore 
critical to the long-term survival of engineered tissues post-
implantation. [14, 16] The degree of vascularization also influences the 
integration of the implanted constructs with the surrounding host 
tissues – increased vascularization generally leads to better integration, 
and may also reduce foreign body reaction and prevent fibrous 
encapsulation. [18, 19] Conversely, if vascularization is slow or 
inefficient, cells within the construct will be unable to survive and host 
cells will fail to infiltrate the construct, resulting in slow healing and poor 




1.1.3. Current vascularization strategies for engineered tissues 
There is therefore a clear need for effective vascularization strategies 
for engineered tissues, and many different approaches have indeed 
been explored, as reviewed in the following sub-sections. The pros and 
cons of each strategy are also summarized in Table 1.1 at the end of 
this section. 
Scaffold design 
There are essentially two conditions that determine whether vascular 
infiltration can occur in an engineered tissue construct. Firstly, the 
scaffold must satisfy a number of basic pre-requisites that make 
angiogenesis physically possible. Secondly, there must be sufficient 
pro-angiogenic stimuli, as angiogenesis is a highly dynamic process 
controlled by a balance between pro-angiogenic and anti-angiogenic 
signals. [20] In other words, there must be a net pro-angiogenic 
stimulus for angiogenesis to occur and progress. Conversely, newly 
formed blood vessels can regress if there are more anti-angiogenic 
signals than pro-angiogenic signals at a given point. Therefore, for 
vascularization to occur in an engineered tissue construct, the 
construct should satisfy the pre-requisites that allow angiogenesis to 
occur, and provide sufficient signals to promote and sustain 
angiogenesis. Vascularization strategies are therefore developed 
based on these two conditions. 
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As angiogenesis is dependent on the ability of cells to infiltrate a tissue, 
the scaffold material should firstly be conducive to cell attachment and 
survival. There are many different strategies for ensuring cell 
attachment to a scaffold. For example, the scaffold can be designed to 
include extracellular matrix proteins, such as collagen, fibronectin, and 
laminin, as human cells adhere readily to these proteins in their natural 
environments in tissues. [21] Alternatively, a synthetic material can also 
be modified to incorporate arginine-glycine-aspartic acid (RGD) 
tripeptide motifs, which are known to facilitate cell attachment by 
binding to integrins on cell membranes. [22, 23] 
Aside from the choice of material, the pore architecture of the scaffold 
is also a crucial determinant of whether angiogenesis can occur. 
Various studies have shown that scaffolds with highly interconnected 
pores with diameters larger than 250 μm are far more conducive to 
angiogenesis than scaffolds with smaller or non-interconnected pores. 
[24-26] Although there are many relatively simple fabrication 
techniques that can produce scaffolds of high porosity (e.g. gas 
foaming and particulate leaching), the resultant pore structure is often 
random and difficult to control. [16] 
Some groups have therefore opted to use rapid prototyping techniques 
to create scaffolds with defined and tuneable pore architectures. [27, 
28] In this method, scaffolds are first designed using computer-aided 
design (CAD) software, then “printed” in three dimensions (3D) using 
automated layer-by-layer manufacturing machinery (also known as “3D 
 9 
 
printers”). This method thus enables scaffold designers to have a high 
degree of control over the resultant scaffold architecture. However, this 
method is still not widely used in clinics due to the relatively high costs 
and time required. [29] 
Incorporation of biochemical cues 
While scaffolds can be designed to be as conducive to angiogenesis as 
possible, there may still not be sufficient pro-angiogenic stimuli to 
induce vascularization at an adequate speed. Vascular infiltration can 
be further improved by incorporating pro-angiogenic factors into the 
scaffold, for example cytokines such as vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), basic fibroblast 
growth factor (bFGF), and hepatocyte growth factor (HGF), or plasmids 
encoding these cytokines. [30, 31] However, as these factors are 
chemically unstable, they have to be used in vastly supraphysiological 
doses, leading to high costs as well as undesirable side effects. 
Notably, PDGF, the only angiogenic growth factor approved by the 
United States Food and Drug Administration for clinical use (as 
Regranex™, by Smith and Nephew, for diabetic leg and foot ulcers), 
was found in a retrospective patient cohort study to increase the risk of 
cancer. [32] In addition, physiological angiogenesis is a complex and 
tightly controlled process that involves interactions between many 
different signalling pathways and factors. Vessels resulting from the 
administration of single angiogenic growth factors are thus often leaky, 
disorganized, and morphologically abnormal. [16] 
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Alternatively, vascularization can also be accelerated by pre-
vascularization. In vivo pre-vascularization utilizes the host’s own 
capacity to grow a bed of microvasculature within an implant over time 
in a suitable location, typically a highly vascularized site such as 
muscle or fascia. This can be accelerated by microsurgical creation of 
an arteriovenous loop around the implant as a source of outgrowing 
vasculature. The vascularized construct is then removed in a second 
surgery and transplanted to the intended site. [33] While this method is 
efficient, the need for multiple surgeries causes additional distress to 
the patient and increases medical costs. In vitro pre-vascularization 
was thus developed as an alternative, which employs endothelial cells 
or endothelial progenitor cells in co-culture with other cell types in the 
tissue engineered construct prior to implantation to form rudimentary 
capillary precursors. Upon implantation, these precursor structures 
may mature into capillaries and anastomose with the patient’s pre-
existing vessels by inosculation. [34, 35] While this method has shown 
great potential, its widespread application in the clinical setting is 
limited because it requires large numbers of autologous cells to be 
expanded ex vivo under good manufacturing practices (GMP)-
compliant conditions, with attendant costs. 
Due to the limitations discussed above, there remains a critical need 
for alternative vascularization strategies that are simple, cost-effective, 













 Relatively high costs 









 Proven efficacy in 
stimulating angiogenic 
sprouting 
 Poor stability and 
short half-life of 
cytokines in vivo, 
resulting in the need 
for supraphysiological 
doses of the cytokines 
 Side effects, including 
increased risk of 
cancer 
 High costs 
 Vessels resulting from 
the administration of 
single angiogenic 












 Plasmids are more 
stable than cytokines 
 A small quantity of 
plasmids can result in 
the production of a 
large quantity of the 
desired angiogenic 
protein 
 Safety concerns 
 Transfection efficiency 
is highly variable 
 Difficulty controlling 
resultant protein 










 Microsurgical creation 
of an arteriovenous 
loop around a 
construct has been 
shown to be effective 
in inducing vascular 
infiltration  
 Need for multiple 
surgeries, resulting in 
additional pain and 
distress to patient 
 Donor site morbidity at 
pre-implantation site 








 Co-culture of 
endothelial cells or 
progenitors with other 
cell types has been 




 Large numbers of at 
least two types of 
autologous cells are 
needed, resulting in 
high costs 
 Long waiting time 
needed for expansion 
of cells 
[16, 35, 41] 
 




1.2. Objectives and thesis scope 
We therefore set out to explore an alternative strategy for 
vascularization, using a class of small molecule drugs known as prolyl 
hydroxylase inhibitors (PHIs), which stimulate angiogenesis by 
stabilizing the transcription factor hypoxia-inducible factor 1 (HIF-1). 
[42] The details of HIF-1 signaling, the mechanisms underlying 
angiogenesis, and our reasons for choosing PHIs are explained in 
detail in the next chapter (chapter 2). 
To determine whether the incorporation of PHIs into scaffolds is a 
viable strategy for stimulating angiogenesis in engineered tissues, we 
conjugated the PHI pyridine-2,4-dicarboxylic acid (PDCA) via amide 
bonds to a gelatin sponge (Gelfoam®). We then characterized this 
construct and investigated its effects on vascularization using a rat 
model of angiogenesis. These experiments constitute the “main branch” 
of this PhD project. The hypotheses, rationales, and experimental 
details pertaining to this main branch are documented in chapter 3 of 
this thesis. 
Aside from its roles in angiogenesis, HIF-1 has also been shown to be 
profoundly involved in osteogenesis and chondrogenesis, and thus 
PHIs may have potential applications in bone. The biology of bone 
formation and the roles of HIF-1 in bone are reviewed in chapter 4. 
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As HIF-1 has multiple roles in bone, PHIs are likely to affect bone cells 
in multiple ways. The functions of PHIs in bone are further complicated 
by the fact that they can also inhibit collagen prolyl 4-hydroxylase 
(P4H), an enzyme that is involved in the synthesis of collagen – an 
integral component of bone. [43, 44] For these reasons, PHIs’ effects in 
bone are highly complex, and there are many unanswered questions 
pertaining to the nature and the extent of their effects. 
We thus performed a preliminary study to investigate PHIs’ effects on 
several aspects of osteoblast behavior in vitro. The hypotheses, 
rationales, and key experiments pertaining to this branch of the PhD 
project (the “side branch”) are explained in detail in chapter 5. This is 
followed by an overarching conclusion that summarizes the main 
findings of this research project, and describes future work stemming 








2.1. Overview of angiogenesis 
In order to develop novel vascularization strategies, it is first important 
to understand the process of angiogenesis and its regulation at the 
cellular and molecular levels. Angiogenesis is defined as the growth of 
new blood vessels from existing vasculature. [45] It is the predominant 
process by which vascularization occurs in adult tissues, and it occurs 
throughout life, beginning in utero and continuing through adulthood. 
[45] A different process for vascularization exists, in which blood 
vessels are assembled de novo from their angioblastic precursors in 
situ – this is known as vasculogenesis, and occurs chiefly during 
embryonic development. [46] Therefore, angiogenesis is far more 
relevant than vasculogenesis in the context of tissue engineering and 
regenerative medicine, and the focus of this literature review is placed 
on angiogenesis accordingly. 
Angiogenesis occurs via a fixed sequence of events: (1) selection of 
sprouting endothelial cells (ECs), (2) sprout outgrowth and guidance, 
(3) sprout fusion and lumen formation, and (4) perfusion and 
maturation (Fig. 2.1). [20] Angiogenic sprouting occurs typically in 
response to hypoxia. (The details of how hypoxia induces angiogenesis 
are explained in the subsequent section.) Under normoxia, blood 
vessels are generally maintained in a quiescent state, controlled by a 
balance of pro-angiogenic and anti-angiogenic signals. When a tissue 
becomes hypoxic, cells within the tissue secrete angiogenic cytokines 




Fig. 2.1. Diagram illustrating the sequence of events in angiogenesis. (Reprinted from 
[20] with permission. Copyright © 2007 Nature Publishing Group.) 
Angiogenesis begins when VEGF binds to a quiescent, VEGF-
responsive EC. Under the effect of VEGF, this EC undergoes a 
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conversion into an active tip cell via a reversal of its apical-basal 
polarity, and becomes highly invasive and motile. [20] The tip cell also 
secretes a signaling protein known as Delta-like ligand 4 (Dll4), which 
binds to Notch receptors in nearby ECs and prevent them from 
becoming tip cells, instead converting them to stalk cells. This process 
serves to prevent excessive ECs from being converted to tip cells, and 
is important to the stability and functionality of the resultant 
vasculature, as an overabundance of tip cells will lead to dysfunctional 
sprouts with too much branching. [47, 48] 
Sprout outgrowth is guided by the tip cell, which extends multiple 
filopodia into its surroundings in search of angiogenic signals. [49] 
Here, VEGF once again plays important roles, by serving as a 
directional cue for sprout outgrowth and by promoting EC proliferation, 
which facilitates the lengthening of the sprouts. Tip cells in the growing 
sprouts secrete platelet-derived growth factor B (PDGF-B), which 
recruits pericytes and vascular smooth muscle cells (collectively known 
as mural cells). [20] These mural cells stabilize the EC-EC junctions 
within the sprouts, maintaining their structural integrity and thereby 
preventing leakage when the sprouts eventually become perfused. 
Perfusion occurs when the growing sprout encounters another sprout 
or capillary under conditions which favor a merger. The precise 
mechanisms which regulate the decision of whether to merge have yet 
to be completely elucidated. Lumen formation is facilitated by the 
formation and merger of multiple vacuoles within the stalk cells, which 
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cause them to become donut-shaped. [20] The newly-formed vessel 
gradually matures as more mural cells are recruited and more 
extracellular matrix is deposited by the cells within the vessel. 
2.2. HIF-1, PHIs and angiogenesis 
2.2.1. HIF-1 structure and function 
As mentioned in the previous section, hypoxia is a key stimulus for 
initiating angiogenic sprouting. As oxygen is crucial to mammalian cell 
survival, mammalian cells have an innate capacity to sense oxygen 
levels in their surroundings. This mechanism and its relation to 
angiogenesis are central to this project, and this section is thus 
dedicated to its explanation in full detail. 
In mammals, cellular and systemic responses to hypoxia are regulated 
by a transcription factor known as hypoxia-inducible factor 1 (HIF-1), a 
heterodimeric protein consisting of an alpha subunit and a beta subunit. 
[50] Both the alpha and beta subunits contain a basic helix-loop-helix 
(bHLH) domain, which recognizes and binds specific DNA motifs, and 
a Per-ARNT-Sim (PAS) domain, which is involved in the 
heterodimerization of the two subunits and their translocation to the 
nucleus. [51] (ARNT stands for aryl hydrocarbon receptor nuclear 
translocator.) Both proteins also contain a C-terminal transactivation 
domain, which recruits HIF-1’s transcriptional co-activators, CREB-
binding protein (CBP) and p300. [52] 
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HIF-1α also contains an oxygen-dependent degradation domain 
(ODDD), which enables it to be regulated in response to oxygen levels 
via a group of structurally-related oxygen-dependent enzymes known 
as HIF-prolyl hydroxylases (HIF-PHDs). [42, 53] HIF-PHDs are 
members of a larger family of redox enzymes known as the 2-
oxoglutarate and iron (II)-dependent dioxygenases. Under normoxia, 
the oxygen-dependent HIF-PHDs hydroxylate the alpha subunit of HIF-
1 (HIF-1α) at proline residues 402 and 564, enabling the von Hippel 
Lindau protein (pVHL) to bind to HIF-1α and ubiquitinate it, thereby 
leading to its rapid degradation via the proteasome pathway. [54] 
Through this mechanism, HIF-1α levels are constantly kept low under 
normal oxygenation conditions, despite being constitutively expressed. 
However, when oxygen levels are low (i.e. when a tissue is hypoxic), 
HIF-PHDs cannot function and HIF-1α is not tagged for degradation. 
This results in the accumulation of HIF-1α, which can then translocate 
to the nucleus and combine with HIF-1β to form the complete 
transcription factor HIF-1. [54] The heterodimeric HIF-1 then recruits 
the co-activators CBP and p300, and facilitates the transcription of a 
multitude of target genes that mediate cellular and systemic responses 
to hypoxia. [54] These responses include metabolic changes, hormone 
secretion, changes in cell behavior, and most importantly in the context 
of this project – angiogenesis. Fig. 2.2 on the next page summarizes 
the signaling pathways involved in the regulation and action of HIF-1, 
while Fig. 2.3 on page 21 shows a list of some known target genes of 




Fig. 2.2. Schematic diagram summarizing the pathways involved in the oxygen-
dependent regulation of HIF-1α and the transcription of target genes by HIF-1. 
Although HIF-1 has a very large number of target genes, only VEGF and glycolytic 
enzymes were shown in this diagram as examples for illustrating how HIF-1 can 
mediate its diverse downstream effects. (Reprinted from [53] with permission. 
Copyright © 2012 Macmillan Publishers Limited.) 
Target genes of HIF-1 have similar sequences (5’-RCGTG-3’), known 
as hypoxia-responsive elements (HREs), in their promoter or enhancer 
regions. [50] These HREs are recognized by the bHLH domain of HIF-
1, and therefore genes preceded by HREs can be transcribed by HIF-
1. Well-known pro-angiogenic target genes of HIF-1 include VEGF, 
fms-like tyrosine kinase 1 (Flt-1, also known as VEGF receptor 1 or 
VEGFR-1), and transforming growth factor beta 3 (TGF-β3). [55-61] 
The precise combination of target genes expressed varies with the cell-
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type, and therefore, HIF-1 can coordinate complex signaling responses 
involving multiple cross-talking cell types. [54]  
 
Fig. 2.3. A list of some known direct transcriptional target genes of HIF-1, categorized 
based on their functions. (Adapted from [55] with permission. Copyright © 2004 
Nature Publishing Group.) 
2.2.2. Molecular regulation of HIF-1 
As a transcription factor, HIF-1 has the unique and invaluable ability to 
modulate a large range of angiogenic factors and thereby coordinate 
the complex multi-cell-type responses needed in angiogenesis. In 
addition, physiological regulation of HIF-1 activity is performed mainly 
by a single class of structurally-similar enzymes (the HIF-PHDs), and 
thus HIF-1 levels can be upregulated simply by inhibiting these 
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enzymes, without the need for complicated and risky techniques such 
as gene transfection. The HIF-PHDs are therefore extremely attractive 
as inhibitory targets for the development of pro-angiogenic drugs. 
In the 1980s, an enzyme closely related to the HIF-PHDs was 
thoroughly characterized as a drug target for treating fibrosis. This 
enzyme, collagen prolyl 4-hydroxylase (P4H), functions via the same 
enzymatic mechanism as the HIF-PHDs. Briefly, these enzymes use 
divalent iron (Fe2+), oxygen, and 2-oxoglutarate to convert proline to 4-
hydroxyproline, in a redox reaction that is coupled to the 
decarboxylation of 2-oxoglutarate to form succinate. [62, 63] Ascorbic 
acid is also required to maintain the reduced state of the divalent iron 
ion under physiological conditions, but is not stoichiometrically 
consumed. [64] In collagens, the resultant hydroxyproline residues are 
needed for hydrogen bond formation within the triple helical tertiary 
structure, which stabilizes the collagens. [65] Therefore, when collagen 
P4H is inhibited, collagen cannot be stabilized and is thus not secreted, 
resulting in decreased collagen deposition. 
Based on the understanding of collagen P4H’s structure, 
stereochemistry, and mechanism of action, a variety of small molecule 
inhibitors of collagen P4H were developed with the aim of treating 
fibrosis. [64] These drugs are collectively known as prolyl hydroxylase 
inhibitors (PHIs), and are typically 2-oxoglutarate analogs, iron 
chelators or active site blockers. [66] Subsequently, when it was 
discovered in 2001 that HIF is also regulated by prolyl hydroxylases, 
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many of these drugs were tested on the HIF-PHDs and found to inhibit 
them as well (Table 2.1). [42, 66] 
 
Table 2.1. A selected list of prolyl hydroxylase inhibitors and their known targets. HIF-
PHDs and collagen P4H are denoted as PHDs and CPH, respectively. FIH 
represents factor inhibiting HIF-1 (discussed below). (Adapted from [66] with 




In 2002, it was discovered that there is another member of the 2-
oxoglutarate and iron (II)-dependent dioxygenase enzyme family that is 
involved in regulating HIF-1. [52] This enzyme is known as factor 
inhibiting HIF-1 (FIH), and is an asparaginyl hydroxylase that 
hydroxylates asparagine residue 803 in the C-terminal transactivation 
domain of HIF-1α. This prevents the recruitment of HIF-1’s 
transcriptional co-activators, CBP and p300, and thus interferes with 
HIF-1’s ability to function as a transcription factor. [52] 
Like HIF-PHDs and other members of the 2-oxoglutarate and iron (II)-
dependent dioxygenase family, FIH requires oxygen to function, and 
thus acts as a second oxygen-sensing regulator of HIF-1 that prevents 
it from functioning under normoxia. Due to the structural and 
mechanistic similarities between FIH and the prolyl hydroxylases, many 
PHIs are also able to inhibit FIH (Table 2.1). This ability to inhibit both 
HIF-PHDs and FIH is highly desirable, as both enzymes have to be 
inhibited for HIF-1 to mediate the transcription of its target genes. In 
addition, FIH also hydroxylates other proteins besides HIF-1, including 
proteins involved in Notch signaling, and may thus have other effects 
that are important in angiogenesis. [67] 
2.2.3. PHIs stimulate angiogenesis 
Various studies have been conducted to evaluate PHIs’ ability to 
stimulate angiogenesis. For instance, Warnecke et al. reported in 2003 
that repeated injections of the PHIs L-mimosine, 3,4-
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dihydroxybenzoate, and 6-chlor-3-hydroxychinolin-2carbonic acid-N-
carboxymethylamid (also known as the proprietary compound 
S956711) into a subcutaneously-implanted polyurethane sponge in rats 
increased angiogenesis. [68] Our group also reported in 2009 that the 
PHIs pyridine-2,4-dicarboxylic acid (PDCA) and hydralazine 
hydrochloride (HDZ) induced ectopic angiogenesis in transgenic 
zebrafish embryos that expressed GFP-labeled blood vessels. [69] 
PDCA and HDZ also significantly increased VEGF secretion by 
fibroblasts and induced co-cultures of fibroblasts and endothelial cells 
to self-assemble into capillary-like structures in vitro. Based on these 
studies, it is clear that PHIs are indeed potent stimulators of 
angiogenesis. 
2.3. Potential applications of PHIs 
2.3.1. Ischemic and fibrotic diseases 
Because HIF-1 has so many downstream targets, and because the 
pattern of expression of these targets varies depending on cell and 
tissue types, PHIs can exert a diverse range of cellular and systemic 
effects through HIF-1, many of which may be clinically useful. These 
effects include metabolic changes such as increased glycolysis, 
immunological changes, increased production of the hormone 
erythropoietin, as well as complex effects on cell survival, proliferation, 
differentiation, and pluripotency. [55, 66, 67] Therefore, PHIs have 
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potential applications in the treatment of many diseases, especially 
those in which anemia and ischemia are underlying factors. 
PHIs also have anti-fibrotic applications due to their ability to inhibit 
collagen P4H. Therefore, PHIs may be particularly useful in diseases 
where both ischemia and fibrosis are involved (e.g. ischemic fibrosis of 
the myocardium and renal ischemia), since they can alleviate and 
protect against ischemic cell death through HIF-PHDs, as well as 
suppress fibrosis by inhibiting collagen deposition. [70, 71] Various 
groups have thus explored the efficacy of PHIs in the treatment of a 
number of such conditions, as reviewed in the next few pages. 
Myocardial infarction and ischemia 
Ockaili et al. reported in 2005 that the PHI dimethyloxalylglycine 
(DMOG) reduces expression and secretion of the pro-inflammatory 
cytokine interleukin 8 (IL-8) by endothelial cells, and that pre-treatment 
with DMOG reduced subsequent infarct size in a rabbit model of 
myocardial ischemia-reperfusion. [72] The same group also reported in 
2006 that silencing of HIF-PHD2 via siRNA administration attenuated 
myocardial ischemia reperfusion injury by stabilizing HIF-1. [73] 
Interestingly, a different group had previously explored the application 
of PHIs for treating myocardial infarctions, but via inhibition of collagen 
P4H instead of HIF-PHDs. [74] They reported that treatment with PHIs 
after myocardial infarction reduced collagen deposition, altered the 
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pattern of left ventricular enlargement, and produced partial recovery of 
left ventricle function in rats. It is thus probable that PHIs can attenuate 
injury and improve post-myocardial infarction recovery via both the 
HIF-PHDs pathway and the collagen P4H pathway, although more 
studies will have to be performed to verify their efficacy. 
Fibrosis 
As discussed in previous sections, PHIs were originally developed as 
anti-fibrotic drugs targeting collagen P4H, and therefore there exists a 
large body of literature studying their effects on various fibrotic 
conditions. One such condition is hypertrophic scars, which occur when 
dermal wounds heal with excessive collagen deposition. Depending on 
the location of the hypertrophic scar, it can pose both functional and 
cosmetic problems. Kim et al. tested the efficacy of the proprietary PHI 
FG-1648 in a rabbit model of cutaneous scarring and showed that it 
significantly reduced scar elevation. [75] 
PHIs have also been tested as treatment for hepatic fibrosis. Fujiwara 
et al. and Bickel et al. separately evaluated two proprietary PHIs, P-
1894B and S4682, respectively, in rat models of liver fibrosis, and both 
groups found that the PHIs inhibited collagen P4H and reduced hepatic 
collagen accumulation, but Fujiwara et al. found that P-1894B did not 





Siddiq et al. explored PHIs’ applications as neurological therapeutics 
for cerebrovascular thrombosis (stroke) and reported that PHIs 
prevented oxidative cell death in cortical neurons in vitro and 
upregulated the HIF target genes enolase, p21, VEGF, and 
erythropoietin in adult rat brains, and that pretreatment with PHIs 
produced neuroprotective effects in a rat model of cerebral ischemia. 
[78] However, as cerebrovascular thrombosis tends to occur without 
warning, the practical applications of PHI pretreatment in the 
prevention of stroke-induced neurological damage may be fairly limited. 
Renal ischemia 
Hypoxia has an important role in the progression of both acute and 
chronic kidney disease, and both fibrosis and loss of microvasculature 
occur in chronic renal disease and tubulointerstitial fibrosis. [79] It was 
thus postulated that PHIs may be useful for preventing ischemia-
reperfusion injury in kidney disease patients. Bernhardt et al. reported 
that pretreatment with the proprietary PHI FG-4487 significantly 
ameliorated subsequent ischemic renal injury in a rat model of acute 
renal failure. [80] 
2.3.2. Wound and fracture healing 
As vascularization is well-known to be critically important to tissue 
regeneration, several groups have explored PHIs’ applications as pro-
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angiogenic drugs for improving tissue healing. These studies are 
focused on two areas – diabetic wounds and fracture healing – likely 
because both of these applications have very large markets. For 
instance, in the U.S. alone, it has been estimated that fractures cost 
27.4 billion dollars per year in expenditures, while another 4.6 to 13.7 
billion dollars are spent annually on the treatment of diabetic peripheral 
neuropathy. [81, 82] In addition, HIF-1 signaling has been found to 
have specialized roles in these two applications aside from stimulating 
angiogenesis, which may make them especially useful in these 
contexts. These roles are discussed in the subsections below.  
Bone regeneration 
While many fractures heal adequately with routine treatment, 
approximately 5-10% of fractures fail to heal and result in non-unions. 
[83] Frequently, this is due to inadequate callus formation resulting 
from an impaired blood supply. [84] The importance of angiogenesis in 
bone development and regeneration is well-established, and 
osteogenesis is always coupled to angiogenesis. [85] HIF-1 plays 
many important roles in this coupling by regulating multiple genes 
necessary for angiogenesis and osteogenesis. In addition, HIF-1 also 
has important roles in chondrogenesis and chondrocyte survival in 
hypoxia. Therefore, HIF-1 is involved in multiple stages of bone 
development and healing. [85] 
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Two studies have been published that demonstrated the utility of PHIs 
in bone regeneration. Wan et al. reported in 2008 that the PHI 
desferrioxamine (DFO) injected every other day directly into the 
distraction gap increased vascularity and accelerated bone 
regeneration in a mouse tibial distraction osteogenesis model. [86] The 
same group also reported in 2009 that injection of the PHIs DFO and 
DMOG into a mouse femoral fracture model increase neoangiogenesis 
and callus formation. [84] The results of these studies suggest that 
PHIs may be useful in promoting non-union fracture healing by 
improving vascularization, callus formation and bone formation. 
Diabetic wounds 
Diabetic patients frequently suffer from chronic wounds and ulcers due 
to impaired wound healing and peripheral neuropathy. Approximately 
15% of diabetic patients will develop a foot ulcer at some point in their 
lives, and about 4% of these foot ulcer patients eventually require lower 
limb amputations. [82] Although chronic wounds are often hypoxic, 
appropriate physiological responses to hypoxia are not activated, 
because high blood glucose levels caused by diabetes impairs the 
binding of HIF-1 to the co-activator p300 and thus prevents HIF-1 from 
functioning as a transcription factor. [87, 88] Interestingly, DFO, a well-
known PHI which is in clinical use as an iron chelator, has been shown 
to be able to salvage HIF-1’s ability to bind to p300 under high glucose 
conditions and restore vascularization and efficient wound healing in 
diabetic mice. [89] Another PHI, ciclopirox olamine (CPX), which is in 
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clinical use as a topical anti-mycotic, was also explored as a treatment 
for diabetic wounds, and it was found to increase availability of HIF-1, 
stimulate angiogenesis, accelerate wound closure, and increase 
dermal cellularity in a diabetic mouse wound splinting model. [90] 
These studies indicate that PHIs have good potential as a treatment for 
diabetic wounds. 
2.4. Potential applications of PHIs in tissue 
engineering 
As reviewed in chapter 1, clinical applications of engineered tissues are 
currently limited mainly to thin or avascular tissues due to a difficulty in 
stimulating adequate vascularization. Current vascularization strategies 
are limited by drawbacks such as inefficacy, high cost, serious side 
effects, and the need for multiple surgeries or large numbers of 
autologous cells. There is thus a need for alternative vascularization 
strategies that are ideally effective, safe, and inexpensive. 
Previous studies performed by our group and by other groups have 
demonstrated that local administration of PHIs can stimulate 
angiogenesis. [68, 69] Other groups have also shown repeated delivery 
of PHIs to diabetic wounds and bone fractures could stimulate 
angiogenesis and accelerate tissue regeneration. [84, 86, 87] These 
studies suggest that PHIs have good clinical potential pro-angiogenic 
agents. However, despite these findings, no studies have been 
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performed to investigate the use of PHIs in tissue engineering 
applications. We thus embarked on a study to evaluate the feasibility of 
using PHIs in engineered tissues. As PHIs are small molecule drugs, 
they are generally cheaper to synthesize and are more chemically 
stable than cytokines such as VEGF. Additionally, by acting through 
the upstream regulator HIF-1, PHIs can upregulate multiple target 
proteins involved in angiogenesis, such as VEGF and VEGFR-1. [55] 
As repeated injections of a drug into an implanted construct would 
cause significant pain and distress to the patient, increase the risk of 
infections, and result in uncontrolled distribution of the drug, a better 
approach for the delivery of PHIs is necessary. We therefore propose 
the use of PHI-delivering scaffolds as a strategy for improving 
vascularization in tissue engineering applications. 
As a proof-of-concept, we incorporated PDCA, a known PHI [43, 69], 
into a gelatin sponge test scaffold by covalent conjugation via amide 
bonds, and evaluated its efficacy in stimulating angiogenic signaling 
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As explained in chapter 1, inadequate vascularization is a major 
bottleneck limiting widespread clinical applications of tissue 
engineering, and current vascularization strategies have critical 
limitations such as high cost, poor stability and shelf-life, complexity of 
implementation, and the need for multiple surgeries or large numbers 
of autologous cells. There is thus a great need for alternative 
vascularization strategies which are simple, cost-effective, reliable and 
safe. 
As small molecule drugs that act through HIF-1, PHIs have the 
advantages of having high chemical stability, low manufacturing costs, 
and most importantly, the ability to modulate multiple signaling 
pathways and co-ordinate the complex processes that occur in 
physiological angiogenesis. As reviewed in chapter 2, several studies 
by our group and by other groups have demonstrated that repeated 
local administration of PHIs can stimulate angiogenesis. In addition, 
other groups have shown that PHIs have other functions that may add 
to their usefulness in specific clinical applications. These advantages 
make PHIs very attractive as pro-angiogenic drugs for tissue 
engineering and regenerative medicine applications. 
As discussed in the previous chapter, repeated injections of PHIs into 
sites of implantation or injury is not feasible due to the associated pain, 
distress and risks of introducing infections. We therefore propose the 
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incorporation of PHIs into scaffolds as an alternative vascularization 
strategy for tissue engineering and regenerative medicine applications. 
3.2. Hypothesis and objectives 
We hypothesized that the incorporation of PHIs into a scaffold for 
subsequent local release would stabilize HIF-1α in infiltrating cells and 
increase vascular infiltration. To assess the feasibility of this strategy, 
we incorporated the PHI pyridine-2,4-dicarboxylic acid (PDCA) into a 
commercially-available gelatin sponge scaffold (Gelfoam®) and used it 
as a proof-of-concept construct. We then characterized the construct, 
assessed its bioactivity in vitro, and evaluated its ability to improve 
vascularization in vivo. 
3.3. Materials and methods 
3.3.1. Preparation of PDCA-Gelfoam 
All reagents used for drug conjugation were purchased from Sigma-
Aldrich (St Louis, MO, USA) unless otherwise stated. Gelfoam® sterile 
gelatin sponge (Pfizer, New York, NY, USA) was first cut into smaller 
pieces with dimensions 2.5 × 2.5 × 0.6 cm and placed into 6-well 
polystyrene tissue culture plates (Greiner Bio-One GmbH, 
Frickenhausen, Germany). The reaction scheme is shown in Fig. 3.1. 
1,1’-carbonyldiimidazole (CDI) and pyridine-2,4-dicarboxylic acid 
monohydrate (PDCA) were weighed separately in 50 ml polypropylene 
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tubes (Greiner Bio-One GmbH). PDCA and CDI were used at a molar 
ratio of 1:3, as PDCA was purchased as in monohydrate form. The CDI 
was first dissolved in anhydrous dimethyl sulfoxide (DMSO) at a 
concentration of 0.3 g/ml. The resultant CDI solution was then added to 
the PDCA dropwise with gentle swirling to avoid excessive 
effervescence, and allowed to react for 1 hour at room temperature to 
allow complete conversion of the carboxylic acid groups in PDCA to 
acyl imidazole groups (“activation”).  
 
Fig. 3.1. Reaction scheme showing the conjugation of PDCA to Gelfoam via amide 
bonds. 1,1’-carbonyldiimidazole (CDI) was used to facilitate formation of the amide 
bonds. PDCA’s carboxylic groups are first converted by CDI into acyl imidazole 
groups (“activation”). Imidazole and carbon dioxide are produced as by-products, with 
the imidazole remaining in solution and the carbon dioxide escaping as 
effervescence. When the activated PDCA is added to Gelfoam, the acyl imidazole 
groups react with the amine groups in Gelfoam to form amide bonds. Imidazole is 
again produced as a by-product. The imidazole is subsequently removed by repeated 
washing of the scaffolds. 
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Subsequently, the activated PDCA solution was filtered through sterile 
Millex-LG 0.2 µm polytetrafluoroethylene (PTFE) syringe filters 
(Millipore, Bedford, MA, USA), and diluted to appropriate 
concentrations with anhydrous DMSO. The concentrations of reactants 
used for each dosage condition, as determined in previous optimization 
experiments, are listed in Table 3.1. The diluted activated PDCA 
solutions were added gradually to each piece of Gelfoam to a total 
volume of 4.5 ml per well, and allowed to react for 5 hours, during 
which the acyl imidazole groups in the activated PDCA reacted with the 
amine groups in Gelfoam to form amide bonds. No-drug controls (“0% 
w/w”) were similarly incubated with plain anhydrous DMSO. At the end 
of the reaction, samples were transferred to individual 50 ml 
polypropylene tubes and washed 10 times with Milli-Q water, with each 
washing step lasting at least 4 hours. The washed samples were then 





Resultant [PDCA] in  
PDCA-Gelfoam (% w/w) 
0 0 0% 
20 60 5% 
190 570 10% 
480 1440 15% 
 
Table 3.1. Concentrations of PDCA and CDI used in the reactant solutions and the 
resultant conjugation yields (i.e. PDCA concentration in PDCA-Gelfoam, in % w/w). 
The concentrations of PDCA and CDI required were determined by extrapolating data 
from previous experiments conducted to establish the relationship between reactant 
concentrations and resultant yields. 
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3.3.2. Drug loading measurements 
The concentration of PDCA in the dissolved PDCA-Gelfoam samples 
was determined by ultraviolet spectroscopy, using an Infinite M200 
plate reader (Tecan, Research Triangle Park, NC, USA) and ultraviolet-
transparent 96-well flat bottom microtiter plates (Greiner Bio-One 
GmbH). PDCA-Gelfoam samples and controls were dissolved at a 
concentration of 20 mg/ml in 6N hydrochloric acid by heating at 95 °C 
for 15 min. The dissolved samples were diluted 1:10 with Milli-Q water 
for spectroscopy, such that the final concentration of hydrochloric acid 
was 0.6N. PDCA standards were prepared in 0.6N hydrochloric acid. 
UV absorption measurements were made at wavelengths from 230 nm 
to 330 nm, at intervals of 5 nm, and UV absorption spectra were 
obtained by plotting absorbance against wavelength. Absorbance 
measurements at 290 nm were used for drug loading calculations, as 
the ratio of the absorbance of PDCA to that of Gelfoam is the greatest 
at 290 nm. Baseline correction was performed by subtracting the 
absorbance of the blank plate and the absorbance of 0.6N hydrochloric 
acid from the absorbances of all samples. A linear PDCA standard 
curve that intersects the origin was then plotted. The absorbance of 
Gelfoam was subtracted from the absorbance of PDCA-samples to 
exclude the absorbance contributions from Gelfoam, and the PDCA 





3.3.3. Scanning electron microscopy 
The morphology and pore structure of the PDCA-Gelfoam scaffolds 
were assessed by scanning electron microscopy (SEM) using a Zeiss 
Supra 55 VP scanning electron microscope (Zeiss, Göttingen, 
Germany) with a variable pressure secondary electron (VPSE) detector 
(magnification = ×100, working distance = 6.8–7.5 mm, EHT voltage = 
10.00 kV). 
3.3.4. Cell culture 
Normal human fetal lung fibroblasts (IMR-90) were purchased from the 
American Tissue Culture Collection (Rockville, MD, USA). Human 
osteosarcoma cells (U2OS) expressing green fluorescent protein-
tagged HIF-1α (GFP-HIF-1α) were purchased from Thermo Scientific 
(Lafayette, CO, USA). All media and supplements used for cell culture 
were purchased from Invitrogen (Carlsbad, CA, USA) unless otherwise 
stated. All reagents were either purchased sterile or sterilized by 
filtration through sterile 0.2 µm filter units. The basal medium used for 
all experiments was high glucose Dulbecco's Modified Eagle Medium 
supplemented with GlutaMAX™ (HG DMEM, Invitrogen, #10569). For 
expansion and maintenance, both cell lines were cultured in HG DMEM 
supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 
10% fetal bovine serum (FBS). For assays, cells were seeded and 
cultured in HG DMEM supplemented with 30 µg/ml L-ascorbic acid 
phosphate magnesium salt n-hydrate (Wako Pure Chemicals, Osaka, 
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Japan), 100 U/ml penicillin, 100 µg/ml streptomycin, and FBS (“assay 
medium”). The percentage of FBS used was 10% for seeding and 2% 
for subsequent medium changes. 
3.3.5. Culturing fibroblasts on PDCA-Gelfoam scaffolds 
PDCA-Gelfoam samples were first cut into 8 mm-diameter cylinders 
using biopsy punches. The cylindrical scaffolds were then disinfected 
by immersion in 70% ethanol and allowed to dry for 30 minutes. Next, 
the scaffolds were immersed in 8% w/v sodium bicarbonate (Sigma-
Aldrich) in culture medium for 5 minutes to neutralize the carboxylic 
acid groups of the conjugated PDCA. The scaffolds were then 
transferred to Transwell™ polycarbonate cell culture inserts in 24-well 
plates (Corning Costar, Corning, NY, USA, #3422), rinsed three times 
with culture medium to remove excess sodium bicarbonate, and 
conditioned with assay medium overnight. IMR-90 fibroblasts between 
passages 16 and 18 were then seeded at a density of 250,000 cells 
per scaffold and allowed to attach for 2 hours, after which 1 ml of 
culture medium was added per well (Fig. 3.2). Culture medium was 
changed 24 hours post-seeding and every 2 days thereafter. Culture 
medium samples harvested during each medium change were either 




Fig. 3.2. Transwell™ polycarbonate cell culture inserts were used to keep the PDCA-
Gelfoam scaffolds upright during culture. 
3.3.6. Cytotoxicity assay 
Cytotoxicity of samples were assessed by analyzing aliquots of freshly 
harvested medium from day 1 post-seeding using a Vybrant 
cytotoxicity assay kit (Invitrogen), which measures the leakage of the 
cytosolic enzyme glucose 6-phosphate dehydrogenase (G6PD) from 
compromised cells. Fluorescence measurements were made using a 
FLUOstar Optima plate reader (BMG Labtech, Durham, NC, USA). 
3.3.7. Quantifying cell numbers in scaffolds 
Samples that had been cultured for 7 days were rinsed three times with 
phosphate buffered saline (PBS). Excess PBS was gently squeezed 
out from the scaffolds and removed. The scaffolds were then 
transferred to individual 1.5 ml polypropylene tubes and digested with 
500 μl of 125 µg/ml papain (Sigma-Aldrich) in PBS containing 5 mM L-
cysteine (Sigma-Aldrich) and 5 mM disodium EDTA (Bio-Rad) at 60 °C 
for 24 hours. The volume of each digested sample was then measured 
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using a micropipette (Eppendorf, Madison, WI, USA). The 
concentration of DNA in each digested sample was then measured 
fluorometrically using a Quant-iT PicoGreen dsDNA assay kit 
(Invitrogen) and a FLUOstar Optima plate reader. The DNA content in 
each scaffold was then calculated by multiplying the concentration of 
DNA by the volume of each digested sample. The cell number was 
then obtained by dividing the DNA content in each scaffold by the 
known quantity of DNA in each diploid human cell (6.6 pg). [91] 
3.3.8. Assessing the distribution of cells within the scaffolds 
To facilitate confocal microscopy, the cylindrical PDCA-Gelfoam 
scaffolds were each cut into two thinner pieces with half the original 
thickness, such that each piece had a thickness of approximately 3 
mm, prior to cell culture. 100,000 IMR-90 fibroblasts between passages 
16 and 18 were seeded on each half-thickness scaffold and cultured 
for 7 days as described in previous sections. Subsequently, the 
scaffolds were rinsed three times with PBS and fixed in 4% w/v 
formaldehyde (Thermo Scientific) in PBS for 48 hours. Cell nuclei in 
scaffolds were then stained with 0.5 µg/ml 4',6-diamidino-2-
phenylindole (DAPI) in PBS for 30 minutes, and rinsed three times 
again with PBS. The scaffolds were then placed on a glass cover slip 
and visualized using an Olympus FV500 laser-scanning confocal 
microscope (Tokyo, Japan). Three-dimensional reconstructions 
showing the positions of the cell nuclei were generated using ImageJ 
software (NIH, Bethesda, MD, USA). 
 43 
 
3.3.9. HIF-1α reporter assay 
To facilitate fluorescence microscopy, the cylindrical PDCA-Gelfoam 
scaffolds were each cut into four thinner pieces, each with a thickness 
of approximately 1.5 mm, prior to cell culture. After sterilization by 
dipping in 70% ethanol, the scaffolds were inserted into a 96-well plate 
(Greiner). The scaffolds were then carefully spread out, such that they 
lay flat in each well and covered the entire bottom of well. The scaffolds 
were then neutralized, rinsed, and conditioned with assay medium 
overnight. GFP-HIF-1α-expressing U2OS osteosarcoma reporter cells 
were labelled using a PKH26 fluorescent cell linker kit (Sigma-Aldrich) 
prior to seeding, so that the cells could be located even in the absence 
of GFP-HIF-1α protein. The labelled cells were then seeded onto the 
quarter-thickness scaffold at a density of 100,000 cells per scaffold and 
cultured for 24 hours. GFP-HIF-1α levels were monitored at 4 hours, 8 
hours, and 24 hours post-seeding using an Olympus IX31 fluorescence 
microscope. 
3.3.10. Analysis of VEGF secretion 
The quantities of VEGF in aliquots of harvested medium were analyzed 
by enzyme-linked immunosorbent assay (ELISA) using a Quantikine 
VEGF ELISA kit (R&D Systems, Minneapolis, MN, USA). Optical 




3.3.11. Rat peri-renal fat implantation model 
All animal experiments were reviewed and approved by the Institutional 
Animal Care and Use Committee of the National University of 
Singapore (NUS IACUC, protocol number 039/09). Ten to twelve 
weeks old male Sprague-Dawley rats purchased from NUS 
Comparative Medicine were used for this study. All PDCA-Gelfoam 
samples used for animal experiments were prepared under aseptic 
conditions using sterile materials and equipment, and all reagents used 
were either purchased sterile or sterilized by autoclaving or filtration 
through sterile 0.2 µm filter units. All surgical procedures were 
performed as described previously. [92] Prior to implantation, 
aseptically-prepared PDCA-Gelfoam samples were cut into 1.0 × 1.0 × 
0.6 cm pieces and disinfected by dipping in sterile-filtered 70% ethanol, 
as an extra safety measure. The samples were then allowed to dry for 
30 minutes, neutralized by immersion in 8% w/v sodium bicarbonate for 
5 minutes, and rinsed three times with PBS. Anesthesia was induced in 
the rats and maintained by intraperitoneal injection of 
ketamine:xylazine (75 mg/kg:10 mg/kg) and inhalational isoflurane 
(2%). Carprofen (5 mg/kg, subcutaneous) was administered 
preoperatively as analgesia. A mid-laparotomy was performed, 
followed by displacement of the gut, mild retraction of the right kidney, 
and blunt preparation of the retroperitoneal fossa. A pouch was created 
between the retrorenal fat and the psoas muscle, and a PDCA-
Gelfoam sample was inserted into the pouch. This was repeated on the 
left side, such that two PDCA-Gelfoam samples from the same dosage 
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condition were implanted in each rat. The bowel was then repositioned, 
and the abdomen closed in two layers of sutures. Carprofen (5 mg/kg, 
subcutaneous, once daily) and enrofloxacin (25 mg/kg, subcutaneous, 
twice daily) were administered for 5 days post-surgery. At 8 days post-
surgery, the rats were euthanized and the PDCA-Gelfoam samples 
were explanted for analysis. 
3.3.12. Preparation of frozen sections 
Explants were fixed in 4% w/v formaldehyde in PBS for 4 hours, 
immersed in 30% w/v sucrose (Sigma-Aldrich) in PBS overnight, and 
frozen-embedded in Tissue-Tek OCT compound (Sakura Finetek, 
Torrance, CA, USA). The samples were then cryosectioned at 10 µm 
thickness. 
3.3.13. Morphometric analysis of vascular infiltration 
Endothelial cells present in explant sections were visualized by 
immunohistochemical staining for rat endothelial cell antigen-1 (RECA-
1), a rat pan-endothelial cell marker. Mouse monoclonal antibodies 
against RECA-1 (1:50, Hycult Biotechnology, Uden, The Netherlands, 
HM3012) were used as the primary antibody, and Alexa Fluor® 594-
conjugated goat anti-mouse IgG (1:400, Invitrogen, A-11032) was used 
as the secondary antibody. Sections were blocked with 3% BSA in 
PBS prior to immunostaining. Primary antibodies were incubated for 16 
hours, and secondary antibodies were incubated for 1 hour. Cell nuclei 
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were counterstained using 0.5 µg/ml DAPI in PBS. Images were 
captured using a Zeiss Axio Observer Z1 microscope (Zeiss, 
Göttingen, Germany). Morphometric analysis of immunostained areas 
and quantification of cell nuclei was performed using ImageJ software. 
3.3.14. Statistical analysis 
Data are presented as mean ± standard error. The statistical 
signiﬁcance between groups was determined by Student’s t-test using 
a two-tailed distribution with unequal variance. Differences were 
considered statistically significant when p < 0.05. 
3.4. Results 
3.4.1. PDCA was successfully conjugated to Gelfoam 
PDCA’s UV spectrum displayed two absorption maxima, one below 
230 nm (the lower limit of the instrument) and one at 280 nm, 
corresponding to the carbonyl bonds in the carboxylic acid groups and 
the pyridine ring, respectively (Fig. 3.3a). [93, 94] The UV spectrum of 
untreated Gelfoam (i.e. in its original state, as purchased from Pfizer) 
also had an absorption maximum below 230 nm, corresponding to the 
carbonyl bonds present in the carboxylic acid and amide groups of 
gelatin, but absorbed relatively weakly in the rest of the wavelength 
range  measured (Fig. 3.3b). [94] The UV spectra of the PDCA-
Gelfoam samples contain spectral characteristics from both PDCA and 
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Gelfoam (Fig. 3.3c), indicating that the conjugation of PDCA to 
Gelfoam via amide bonds using CDI had been successful. Absorption 
at both 230 nm and 280 nm increased as the concentration of 
reactants used increased, showing that more PDCA was successfully 
conjugated to the Gelfoam when higher concentrations of reactants 
were used. Drug loading measurements (Fig. 3.3c; expressed in % 
w/w) were calculated using absorbance values measured at 290 nm, 
by subtracting the absorbance contribution of Gelfoam and back-
calculating the concentration of PDCA from a PDCA standard curve.  
3.4.2. Gelfoam retains high porosity after PDCA conjugation 
The physical appearance and morphology of untreated Gelfoam (i.e. 
Gelfoam in its original form, as purchased from Pfizer) and PDCA-
Gelfoam samples are shown in Fig. 3.4. Compared with the untreated 
Gelfoam, the treated PDCA-Gelfoam samples had a rougher texture 
and slightly smaller pores, but remained highly porous. The 
morphology of the PDCA-Gelfoam samples appeared similar across all 
dosages, with and without PDCA, suggesting that morphology is 





Fig. 3.3. UV absorbance spectra of (a) 1 mM PDCA, (b) untreated Gelfoam, and (c) 
PDCA-Gelfoam samples (0% to 15% w/w), generated from absorbance readings 
measured between 230 nm (the lower limit of the instrument) and 330 nm at 5 nm 
intervals. The spectra of the PDCA-Gelfoam samples contain spectral characteristics 
from both PDCA and Gelfoam, indicating that drug conjugation was successful. Drug 
loading measurements (expressed in % w/w) were calculated using absorbance 




Fig. 3.4. (a) Photographs (scale bar = 5 mm) and (b) scanning electron microscopy 
images (scale bar = 100 µm) showing the physical appearance and morphology of 





3.4.3. PDCA-Gelfoam has low cytotoxicity and supports cell 
attachment, proliferation, and infiltration 
Cytotoxicity test results obtained using Invitrogen’s Vybrant G6PD 
leakage assay show that PDCA-Gelfoam has low cytotoxicity (<10%) at 
all dosages tested (Fig. 3.5a). Cell numbers measured using 
PicoGreen-based DNA measurements showed that by day 7, the cells 
had proliferated far beyond the numbers seeded (250,000 cells), 
ascertaining that PDCA-Gelfoam can support cell proliferation (Fig. 
3.5b). Cell numbers at higher dosages (10% and 15% w/w) were, 
however, significantly lower than in controls (0% w/w), suggesting a 
dose-dependent anti-proliferative effect consistent with prior literature 
that showed that PHIs can reduce cell proliferation without affecting cell 
viability. [95, 96] Three-dimensional confocal reconstructions of DAPI-
stained PDCA-Gelfoam samples showed that cells had infiltrated the 
scaffolds extensively by day 7 of in vitro culture (Fig. 3.6), proving that 
the conjugated PDCA did not interfere with cell attachment and 





Fig. 3.5. (a) Cytotoxicity was monitored by measuring the leakage of G6PD from 
compromised cells, using Invitrogen’s Vybrant cytotoxicity assay. Results show that 
PDCA-Gelfoam has low cytotoxicity (<10% compared to positive control) at all 
dosages tested. (n = 3. Error bars represent standard error.) (b) Cell proliferation was 
assessed by harvesting the scaffolds after 7 days of in vitro culture, digesting the 
scaffolds with papain, and measuring the DNA content using PicoGreen. Cell 
numbers at day 7 were 2 to 4 times higher than the 250,000 cells that were initially 
seeded (indicated by the blue dotted line), demonstrating that PDCA-Gelfoam 




Fig. 3.6. Cell infiltration and attachment was visualized by confocal imaging. 
Scaffolds were harvested after 7 days of in vitro culture, stained with DAPI, and 
imaged under a confocal microscope. Three-dimensional reconstructions generated 
using the z-stacks showed that the scaffolds supported good cell infiltration and 
attachment at all dosages tested. Labels on the bounding box indicate the scale in 
µm (each unit = 100 µm).  
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3.4.4. HIF-1α is stabilized in a dose-dependent manner in cells 
growing on PDCA-Gelfoam 
Reporter cells transfected with GFP-tagged HIF-1α were cultured on 
thinly-sliced PDCA-Gelfoam scaffolds and imaged at 24 hours post-
seeding (Fig. 3.7). The levels of GFP-HIF-1α were below the limit of 
detection in the controls (0% w/w), as well as the lowest dosage (5% 
w/w). At the higher dosages (10% and 15% w/w), GFP-HIF-1α was 
sufficiently stabilized that their levels were detectable as green 
fluorescence, with the highest levels observed at 15% w/w. These 
results demonstrate that PDCA-Gelfoam can release PDCA and 
stabilize HIF-1α in infiltrating cells. 
3.4.5. PDCA-Gelfoam stimulates VEGF secretion by fibroblasts 
in vitro 
As VEGF is an important pro-angiogenic cytokine and a direct 
transcriptional target of HIF-1, we assessed VEGF secretion as a 
marker for PDCA-Gelfoam’s effects on HIF-1 downstream signaling. 
Fibroblasts were cultured for 24 hours on PDCA-Gelfoam scaffolds, 
after which the VEGF content of the culture medium was analysed by 
ELISA. Results showed that the higher PDCA dosages (10% and 15% 





Fig. 3.7. GFP-HIF-1α-transfected reporter cells were labelled with PKH26 membrane 
dye (orange), seeded on PDCA-Gelfoam scaffolds, and imaged 24 hours later. The 
amount of HIF-1α present (green GFP fluorescence localized to cell nuclei) increased 
as the PDCA content of the scaffolds increased, demonstrating a dose-dependent 





Fig. 3.8. VEGF measurements performed on conditioned medium samples from day 
1 of in vitro culture of fibroblasts on PDCA-Gelfoam scaffolds showed that scaffolds 
with higher PDCA content (10% and 15% w/w) significantly increased VEGF 





3.4.6. PDCA-Gelfoam stimulates vascular infiltration in vivo 
PDCA-Gelfoam samples were implanted into the peri-renal fat tissue of 
Sprague Dawley rats (Fig. 3.9a), and explanted 8 days later (Fig. 3.9b). 
It was observed that the sizes of the explants decreased as the PDCA 
content in the scaffolds increased. This was due in part to differences 
in the scaffolds’ degradation rates, as the conjugated PDCA increased 
the hydrophilicity of the scaffolds. 
 
Fig. 3.9. (a) PDCA-Gelfoam samples were implanted into the peri-renal fat of 
Sprague Dawley rats to assess their effects on vascular infiltration in vivo. (b) 
Appearance of PDCA-Gelfoam explants at day 8 post-implantation. The scaffolds 
were harvested with some of the surrounding peri-renal fat intact to minimize damage 
to the scaffolds and the vasculature. Scale bar = 5 mm. 
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To assess PDCA-Gelfoam’s effects on vascular infiltration, explant 
crysoections were immunostained for RECA-1, a rat pan-endothelial 
cell marker, and counterstained for cell nuclei using DAPI. We 
observed that all explants were well-infiltrated by cells, confirming that 
PDCA-Gelfoam supported good cell attachment and infiltration at all 
dosages tested (Fig. 3.10). The higher dosages (10% and 15% w/w) 
also had visibly more endothelial cells than the 0% w/w controls (Fig. 
3.10). 
To compare the degrees of vascular infiltration across different 
dosages, the percentages of RECA-1-positive areas in the sections 
were quantified morphometrically (Fig. 3.11a). Results showed that the 
conjugated PDCA increased vascular infiltration in a dose-dependent 
manner, with the two highest dosages (10% and 15% w/w) having the 
most pronounced increases in endothelial cell density (7.3-fold and 8.9-
fold, respectively). To rule out the influence of cell density variations, 
the numbers of nuclei present were counted using ImageJ, and the 
percentages of RECA-1 positive areas were normalized to the cell 
numbers and plotted (Fig. 3.11b). Results showed that the dose-
dependent trend of increase in vascular infiltration remained similar 
after normalization to cell numbers, indicating that the observed 
increases in vascular infiltration were not due to cell density variations. 
Taken together, our results have conclusively demonstrated that the 





Fig. 3.10. DAPI nuclei staining (blue) of explant cryosections shows that the samples 
were well-infiltrated by cells by 8 days post-implantation. RECA-1 
immunofluorescence (red) shows the distribution of endothelial cells with the 
explants. White dotted lines delineate the edges of the scaffolds. The samples with 
higher PDCA dosages (10% and 15% w/w) have visibly higher densities of 
endothelial cells. It is also notable that while endothelial cells were present in the 0% 
and 5% w/w cells, they were mostly localized to the edges of the explants; by 
contrast, endothelial cells present in the 10% and 15% w/w samples were distributed 






Fig. 3.11. (a) To quantitatively compare  the degrees of vascular infiltration, the 
percentage of RECA-1-positive areas was quantified in ImageJ and plotted. Results 
show that at the higher dosages (10% and 15% w/w), vascular infiltration was 
substantially increased. (b) To rule out the influence of variations in cell density, the 
number of cell nuclei per section was also quantified in ImageJ, and the percentage 
of RECA-1-positive areas were normalized to cell density and plotted. Comparison of 
the normalized and un-normalized graphs shows that the trend remains similar after 
normalization to cell numbers, and the observed increase in the quantity of 
endothelial cells in the higher dosages is not due to differences in general cell 





In this study, we have demonstrated for the first time the feasibility of 
stimulating vascularization by incorporating a PHI into a scaffold for 
subsequent local release. PDCA was selected as the PHI of choice on 
the basis of its low cytotoxicity and its good efficacy in stabilizing HIF-
1α, as shown in previous experiments performed by our group. [97] 
PDCA also has two intrinsic carboxylic acid groups, which can be used 
to conjugate it to scaffolds via either amide bonds or ester bonds. 
Gelfoam, a commercially available gelatin sponge, was selected as our 
test scaffold because of its ease of handling and its safety, as 
demonstrated by its widespread clinical use. [98] 
We conjugated PDCA to Gelfoam via amide bonds by making use of 
the intrinsic carboxylic acid groups in PDCA and the amine groups in 
Gelfoam. The PDCA can then be released when the amide bonds are 
cleaved by proteases from infiltrating cells. Because the amide bonds 
are formed directly between the PHI and the scaffold, additional 
crosslinkers were not needed, eliminating the issues of toxicity and 
immunogenicity associated with the use of crosslinkers such as 
glutaraldehyde and formaldehyde. [99, 100] Degradation products 
formed during the hydrolysis of PDCA-Gelfoam are also unlikely to be 




Our results have shown that PDCA incorporated into a gelatin scaffold 
by conjugation via amide bonds can stimulate angiogenic signaling and 
improve vascular infiltration of the scaffold by stabilizing HIF-1α in 
infiltrating cells. Our findings complement prior work demonstrating that 
repeated injections of the PHIs L-mimosine, 3,4-dihydroxybenzoate, 
and 6-chlor-3-hydroxychinolin-2-carbonic acid-N-carboxymethylamid 
(S956711) into subcutaneously implanted polyurethane sponges in rats 
stimulated angiogenesis, and that local injections of the PHIs 
desferrioxamine (DFO), L-mimosine, and dimethyloxalylglycine 
(DMOG) into femoral fractures in rats increased neovascularization and 
callus formation. [68, 84] 
In a clinical context, repeated injections of drugs into a site of injury 
cause considerable pain and distress to patients and may increase the 
risk of infections. The site of implantation may also be located in 
tissues which are not easily accessible, such as the heart or the spine. 
Incorporation of drugs into implants for subsequent local delivery is 
therefore preferable. We thus conjugated PDCA directly to the scaffold 
via amide bonds, using its intrinsic carboxylic acid groups. Gelfoam 
was selected as the test scaffold in this study because it is 
commercially available, well characterized, and in widespread clinical 
use, but any biomaterial that has amine groups should be amenable to 
the conjugation of PDCA via amide bonds. 
In addition to stimulating angiogenesis, PHIs also have other clinically 
relevant effects that are mediated by other transcriptional targets of 
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HIF-1 unrelated to angiogenesis. HIF-1’s diverse range of targets 
enables it to perform pivotal functions in oxygen sensing, homeostasis, 
and signaling across different tissues. These functions include roles in 
skeletal development, such as osteogenesis and chondrogenesis, as 
well as the coupling of angiogenesis to these processes. [85, 101, 102] 
Therefore, PHIs have promising therapeutic potential in the fields of 
fracture repair and bone tissue engineering. 
Another notable clinical application of PHIs is as anti-fibrotic drugs, 
which is mediated by their ability to inhibit collagen 4-prolyl 
hydroxylase, an enzyme which is structurally related to HIF prolyl 
hydroxylases. [43] Inhibition of this enzyme interferes with the post-
translational modification of procollagen, leading to decreased collagen 
output and thus reduced fibrosis. This anti-fibrotic capacity makes PHIs 
especially useful in situations where both an increase in angiogenesis 
and a reduction in fibrosis are desired, for example in post-myocardial 
infarction treatment. [74] HIF-1 is also known to have a cardioprotective 
effect. [103-105] These findings suggest that PHI-delivering scaffolds 
may also be useful in cardiac tissue regeneration. 
3.6. Conclusion 
As cells cannot survive without an adequate supply of oxygen and 
nutrients, it is crucial to the future of the tissue engineering field that the 
problem of inadequate vascularization be solved. Our findings have 
demonstrated that the incorporation of PHIs into scaffolds is a feasible 
 63 
 
strategy for stimulating vascular infiltration into implanted tissue 
engineered constructs. This strategy may also be used in conjunction 
with cell-based strategies such as in vitro or in vivo pre-vascularization 




Chapter 4  
HIF-1 and the Potential Roles of  







As discussed in chapter 2, HIF-1 has important roles in both 
angiogenesis and osteogenesis, as well as in the coupling of these 
processes during bone formation. All of these functions are important in 
bone regeneration, and studies have shown that PHIs can improve 
callus formation, increase vascularity, and accelerate bone formation in 
mouse fracture models. [84, 86] Based on this information, we 
postulate that PHI-delivering biomaterials may have many applications 
in fracture healing and bone tissue engineering. In this chapter, we 
review HIF-1’s complex and intricate roles in bone development and 
regeneration. 
4.2. Bone development and regeneration 
4.2.1. Mechanisms of bone formation 
Bone formation during normal development and growth occurs via 
either of two mechanisms: (1) intramembranous ossification, which is 
responsible for the development of the flat bones of the skull, and (2) 
endochondral ossification, the mechanism by which long bones 
develop. [106] In intramembranous ossification, mesenchymal 
progenitors differentiate directly into osteoblasts, which deposit osteoid 
and mineralize the bone matrix. [106, 107] In endochondral 
ossification, mesenchymal progenitors first differentiate into 
chondrocytes, which produce a cartilaginous extracellular matrix that 
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forms the growth plate. The chondrocytes continue proliferating and 
differentiating while secreting matrix proteins, eventually becoming 
post-mitotic hypertrophic chondrocytes, which start the mineralization 
process and die off by apoptosis. Blood vessels then begin infiltrating 
the growth plate and bringing circulating mesenchymal progenitors, 
which differentiate into osteoblasts. These osteoblasts then remodel 
and replace the cartilaginous matrix with mineralized bone. [106, 107]  
4.2.2. Bone regeneration during fracture healing 
Bone regeneration during fracture healing also occurs via either 
intramembranous or endochondral ossification. [108] However, the 
process is much more complex than bone formation during normal 
development and growth, as it is influenced by additional factors such 
as immune responses, vascularity, and mechanical signals (Fig. 4.1). 
[108] For example, different degrees of mechanical stability of the 
fractured bone fragments lead to different bone healing responses. 
Stable fixation of the fragments induces direct bone formation via 
intramembranous ossification, while small interfragmentary movements 
caused by slight instability promotes callus formation and healing via 
endochondral ossification. Unstable fixation, on the other hand, inhibits 
bone healing. [109, 110] Stability also influences vascularization, which 
as reviewed in chapter 1, is pivotal to bone healing. Small 
interfragmentary movements promote vascularization during early 
fracture healing, but stable fixation during later phases of healing 




Fig. 4.1. Influence of various factors on the different phases of fracture healing. 
(Reprinted from [108] with permission. Copyright © 2012 Macmillan Publishers 
Limited.) 
Fracture healing consists of three highly regulated and overlapping 
phases: (1) inflammation, (2) repair, and (3) remodeling. [108] In the 
first inflammatory phase, ruptured blood vessels and damaged tissues 
in the fracture site secrete pro-inflammatory cytokines, such as IL-1, IL-
6, and tumor necrosis factor alpha (TNF-α), which initiate an 
inflammatory cascade. [108, 113] Exudation of plasma and leukocytes 
leads to the formation of a hematoma within the fracture gap. [108, 
114] This hematoma serves as a temporary scaffold for the invasion of 
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inflammatory cells, beginning with neutrophils and followed by 
macrophages and lymphocytes. [108] 
During the inflammatory phase, hypoxia within the hematoma also 
stimulates cells within the hematoma to secrete angiogenic factors 
such as VEGF via the HIF-1 pathway, as reviewed in chapter 2, thus 
initiating the revascularization process necessary for fracture healing. 
[108] Impaired or disturbed vascularity is a major cause of fracture non-
union and delayed healing, reflecting the importance of vascularization 
in bone formation and regeneration. [115, 116] 
The second phase is the repair phase, during which bone formation 
occurs. As discussed earlier in this section, bone formation can occur 
via either intramembranous or endochondral ossification, depending on 
two factors: (1) the stability of the fracture, and (2) the location of the 
fracture. Intramembranous ossification is favored in primary cortical 
bone with good fixation, typically provided by bone plates and screws. 
[108, 116] By contrast, diaphyseal fractures stabilized using plaster 
casts tend to be slightly unstable and will typically heal via 
endochondral ossification, which involves the formation of a soft 
cartilaginous callus by chondrocytes This callus is then gradually 
replaced by bone formed by osteoblasts in a process that parallels 
endochondral ossification during long bone development. [108] Bone 
formation typically begins at regions where the newly-formed blood 
vessels and the periosteum are least disturbed by trauma and 
interfragmentary movement. [117] This observation is consistent with 
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the established notion that osteogenesis is always coupled to 
angiogenesis. 
As new bone forms and fills the fracture gap, the callus is gradually 
resorbed by osteoclasts. In the final remodeling phase, the newly 
formed bone in the fracture gap is remodeled, with cortical bone being 
converted to lamellar bone by osteon formation. [108] This phase 
restores the normal architecture and mechanical strength of the bone, 
and completes the fracture healing process. 
4.3. The roles of HIF-1 in bone 
As discussed previously, HIF-1 has multiple important roles in bone 
development and regeneration. These roles can be classified under 
three categories: (1) promoting chondrocyte survival in hypoxia, (2) 
stimulating angiogenesis, and (3) regulatory roles in chondrogenic and 
osteogenic differentiation. 
4.3.1. HIF-1 and chondrocyte survival in hypoxia 
Conditional deletion of HIF-1α in the limb bud mesenchyme or 
chondrocytes of mice resulted in massive cell death of the inner 
chondrocyte layer in the developing growth plate, indicating a role for 
HIF-1 in chondrocyte survival. [118] Conditional knockout of VEGF-A in 
chondrocytes also caused chondrocyte death in the center of the 
growth plates, in a manner similar to that in chondrocytes with deleted 
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HIF-1α, suggesting that HIF-1 mediates survival at least in part through 
upregulation of VEGF, which is a target gene of HIF-1, as well as a 
potent angiogenic and anti-apoptotic cytokine. [119] 
Another way in which HIF-1 can promote survival of chondrocytes in 
hypoxia is by inducing metabolic changes. [106] HIF-1 is known to 
promote glycolysis through several of its target genes, such as glucose 
transporter 1 (GLUT1), which facilitates glucose uptake into cells, and 
enzymes involved in glycolysis, such as phoshoglycero-kinase 1 
(PGK1) and lactate dehydrogenase (LDH). [120-123]  By increasing 
glucose uptake and glycolytic enzymes, HIF-1 enables cells in low 
oxygen conditions to generate sufficient energy via glycolysis. 
Furthermore, HIF-1 also upregulates pyruvate dehydrogenase kinase 
(PDK), which phosphorylates and inhibits pyruvate dehydrogenase. 
This prevents pyruvate from being converted to acetyl coenzyme A 
(CoA) and entering the citric acid cycle, and thus restricts mitochondrial 
respiration and diminishes the resultant oxidative stress, thereby 
promoting cell survival. [124, 125] 
4.3.2. HIF-1’s role in angiogenesis and osteogenesis 
The mechanisms by which HIF-1 stimulates angiogenesis have been 
thoroughly reviewed in chapter 2 of this thesis, as it is a central 
principle in this project. By promoting vascularization of the callus (in 
fracture healing) or growth plate (in bone development and growth), 
HIF-1 both ensures that the oxygen and nutrient demands of the cells 
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are met, and also enables circulating mesenchymal progenitors to be 
brought to the site of bone regeneration for differentiation into 
osteoblasts. 
HIF-1 also has important roles in the coupling of osteogenesis to 
angiogenesis. [85, 101, 126] Studies of bone formation during embryo 
development and fracture healing have shown that osteogenesis and 
angiogenesis are always coupled both temporally and spatially. [101] 
This implies that there are specific mechanisms which couple 
osteogenesis to angiogenesis. 
In genetically modified mice where HIF-1α was constantly stabilized in 
osteoblasts by conditional knockout of pVHL, marked increases in 
vasculature as well as bone density and volume were observed, and 
the increases in bone quantity were proportional to the increase in 
skeletal vasculature. [101, 127] Analysis of mRNA in femur bone tissue 
of these rats also showed that VEGF expression was increased, 
consistent with the fact that VEGF is a direct target of HIF-1. 
Conversely, conditional knockout of HIF-1α in mice resulted in 
significantly thinner long bones with less vasculature. [127] 
Interestingly, deletion of HIF-1α in osteoblasts in vitro resulted in 
increased expression and production of HIF-2α, another HIF isoform 
that has some partial overlap in function with HIF-1α, suggesting that 




While the mechanisms that regulate the coupling of osteogenesis have 
yet to be fully elucidated, it is very likely that VEGF signaling has a 
central role. Aside from its well-known angiogenic effects, VEGF is also 
known to have autocrine effects in osteoblasts and mesenchymal stem 
cells, which express both VEGF and VEGFR-1 (Fig. 4.2). [85] For 
example, VEGF is known to stimulate chemotactic migration of both 
osteoblasts and mesenchymal progenitor cells, enhance osteoblast 
differentiation, and promote osteoblast survival. [128-131] Both VEGF 
and VEGFR-1 are known to be target genes of HIF-1, and indeed, both 
have been shown to be upregulated by mesenchymal stem cells in 
hypoxic conditions. [55, 132] Therefore, it is highly plausible that HIF-1 
signaling improves osteoblast differentiation, migration, and survival by 
increasing VEGF autocrine signaling through upregulation of both 
VEGF and VEGFR-1. 
Aside from effects mediated through VEGF, HIF-1 is also known to 
have target genes that are directly involved in osteogenic and 




Fig. 4.2. Diagram summarizing HIF-1 and VEGF’s differential effects on endothelial 
cells and osteoblasts. Through upregulation of VEGF, HIF-1 stimulates endothelial 
cells to form blood vessels, and promotes chemotactic migration, osteogenic 
differentiation, and survival of osteoblasts. (Reprinted from [85] with permission. 




4.3.3. HIF-1 in osteogenic and chondrogenic differentiation 
Osteoblasts and chondrocytes are both believed to originate from 
undifferentiated mesenchymal progenitor cells. [85, 133] These 
pluripotent mesenchymal progenitors can differentiate along a number 
of lineages, and their commitment to each lineage is regulated by 
several key lineage-specific transcription factors. Two of these 
transcription factors, osterix (Osx, also known as sp7) and sex-
determining region Y-box 9 (Sox9), which are respectively involved in 
osteogenic and chondrogenic differentiation, have been proven in 
chromatin immunoprecipitation and promoter analysis studies to be 
different target genes of HIF-1. [85, 133] Therefore, HIF-1 appears to 
have important roles in regulating the lineage and stage of 
differentiation in response to changes in oxygen levels. 
Osterix is a zinc finger-containing transcription factor that is well known 
to be necessary for normal osteoblast differentiation and bone 
formation. [134] In Osx-null knockout mice, no bone formation occurs, 
and postnatal inactivation of Osx in Osxfloxed/- mice resulted in severely 
altered bone structures with massive accumulation of calcified 
cartilage. [134, 135] Relatively little is known about the specific 
mechanisms by which osterix regulates osteoblast differentiation and 
function, although the vitamin D receptor has been identified as a 
target gene of Osx. [136] 
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Sox9 is a high-mobility-group domain transcription factor that is 
expressed in chondrocytes, as well as some other tissues, such as the 
nervous and urogenital systems. [137] In humans, Sox9 
haploinsufficiency results in a lethal skeletal malformation syndrome 
known as campomelic dysplasia, as well as XY sex reversal. [137, 138] 
Inactivation of Sox9 in the chondrocytes of mice results in severe 
chondrodysplasia, and chimeric mice generated using a mixture of 
Sox9-/- and wild type embryonic stem cells developed cartilage 
abnormalities proportionate with the percentage of Sox9-/- cells. [137, 
139] Analysis of the cartilage in the chimeric mice also revealed that 
chondrocytes present in their cartilage were exclusively wild type, 
suggesting that progenitor cells that lack Sox9 could not differentiate 
into chondrocytes. [137] 
Studies of skeletal development in mice revealed that mesenchymal 
stem cells differentiate into chondrocytes in an avascular environment, 
and condensed mesenchymal cells in the limb had high levels of HIF-
1α protein. [133, 140, 141] Conditional knockout of HIF-1α in the limb 
mesenchyme of genetically modified mouse embryos resulted in 
impaired and delayed skeletal development, resulting in shorter, 
deformed, and less mineralized bone, and joint fusion in the elbow, 
knee, and phalangeal joints. [133] Analysis of protein expression in the 
resultant embryos also showed that knockout of HIF-1α resulted in the 
sequential loss of Sox9, Sox6, collagen II, and aggrecan expression, 
suggesting that HIF-1α is necessary for differentiation of pre-
chondrogenic progenitors into chondrocytes. [133] 
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Based on the literature reviewed above, it can be seen that HIF-1 has 
many important and intricate functions in bone formation during 
development and healing.  Since PHIs stabilize HIF-1, it is plausible 
that they may have many applications in bone regeneration. This idea 
is explored in the subsequent section. 
4.4. PHIs in bone regeneration 
There are many situations where bone grafts or substitutes are needed 
to facilitate proper bone regeneration, for example in skeletal and 
maxillofacial reconstruction, neurosurgery, spinal surgery, joint 
arthroplasties, and various sports medicine procedures. [142, 143] 
Approximately 2.2 million bone grafts are performed annually 
worldwide, costing an estimated $2.5 billion per year. [142] Autografts 
are limited by problems such as donor-site morbidity and availability, 
while allografts are associated with immunogenicity and risk of disease 
transmission. [142] Bone graft substitutes and engineered bone tissue 
are thus highly coveted as possible alternatives, but clinical feasibility 
of many of these devices remain hampered by insufficient 
vascularization. [144] As discussed in previous sections, angiogenesis 
is required for osteogenesis, and thus inadequate vascularization has 
been identified as a major reason for the failure of such bone implants. 
[144] 
In previous sections, it has been established that HIF-1 has many 
important roles in both angiogenesis and bone formation, and 
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therefore, PHIs have considerable therapeutic potential in the field of 
bone regeneration. Indeed, two studies have explored PHI effects on 
fracture healing. Using a mouse distraction osteogenesis model, Wan 
et al. showed that the PHI desferrioxamine (DFO), injected into the 
distraction gap every other day from days 7 to 17 post-surgery, 
significantly increased bone volume and vessel density, number, and 
connectivity. [86] Shen et al. demonstrated in a mouse femoral fracture 
model that repeated injections of the PHIs DFO and 
dimethyloxalylglycine (DMOG) into the fracture site every other day for 
five doses significantly increased callus size, bone volume, as well as 
vessel number, volume, and density. [84] Based on these studies, it 
can be seen that repeated administration of PHIs into a bone defect 
can increase angiogenesis and accelerate callus and bone formation. 
These results suggest that PHIs have promising therapeutic potential in 




Chapter 5  
Effects of PHIs on Osteoblasts:  






As reviewed in the previous chapters, HIF-1 is highly involved in the 
processes of angiogenesis and bone formation, and repeated 
injections of PHIs into bone defects have been shown to be beneficial 
to angiogenesis, callus formation, and bone regeneration in mouse 
models. [84, 86] However, very few studies have been done to 
investigate the effects of PHI exposure on osteoblast viability, signaling, 
and differentiation, and there are still many unanswered questions 
regarding how PHIs can be best applied to bone regeneration. In 
addition, it is known that PHIs can reduce collagen secretion by 
inhibiting collagen P4H, and this may complicate PHIs’ effects on bone 
regeneration, considering that collagen is an important component of 
bone. [43, 44] We therefore embarked on a preliminary study to assess 
and characterize some of the effects that PHIs have on osteoblast 
behavior. 
5.2. Hypotheses and objectives 
Based on prior literature, we hypothesized that PHIs should stabilize 
HIF-1α in osteoblasts and upregulate VEGF and osterix, both of which 
are direct transcriptional targets of HIF-1. However, as PHIs also inhibit 
collagen P4H, they are likely to reduce the production of type I collagen, 
which is an important component of bone and is known to serve 
scaffold for subsequent mineral deposition. [145] As the simultaneous 
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stabilization of HIF-1α and inhibition of collagen production by PHIs 
may have conflicting effects on osteoblast differentiation and 
mineralization, we were interested to explore the effects. 
5.3. Materials and methods 
5.3.1. Osteoblast culture 
All media and supplements used for cell culture were purchased from 
Invitrogen (Carlsbad, CA, USA) unless otherwise stated. Primary 
normal human osteoblasts (NHOsts) were purchased at passage 2 
from Lonza (Basel, Switzerland). 
For expansion, the NHOsts were cultured in low glucose Dulbecco’s 
Modified Eagle Medium containing GlutaMAX™ (LG DMEM, 
Invitrogen, #10567), supplemented with 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 10% fetal bovine serum (FBS). 
For assays, NHOsts were cultured in “osteoblast assay medium”, 
which consists of high glucose DMEM containing GlutaMAX™ (HG 
DMEM, Invitrogen, #10569), supplemented with 100 U/ml penicillin, 
100 µg/ml streptomycin, and 10% FBS. For osteogenic induction, 
NHOsts were cultured in osteoblast assay medium further 
supplemented with osteogenic induction supplements, namely 30 μM 
L-ascorbic acid magnesium phosphate (Wako Pure Chemicals, Osaka, 
Japan), 100 nM dexamethasone (Sigma-Aldrich, St Louis, MO, USA), 
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and 10 μM beta-glycerophosphate (Calbiochem, San Diego, CA, USA), 
while NHOsts in non-induced treatment groups were cultured in 
osteoblast assay medium without further supplements. 
5.3.2. Preparation of PHIs for drug treatment 
All reagents used for preparation of PHI stock solutions were 
purchased from Sigma-Aldrich. All PHI stocks and treatment media 
were prepared immediately before the experiment and used for 1 week 
at the longest, unless otherwise stated. 
Pyridine-2,4-dicarboxylic acid monohydrate (PDCA) was dissolved in 
HG DMEM (Invitrogen) together with an equal mass of sodium 
bicarbonate (in slight excess) to neutralize the acid group to form a 300 
μM (30x) stock solution. Ciclopirox olamine (CPX) was dissolved in 
methanol at a concentration of 500 mM, divided into single-use 
aliquots, and stored at –20°C. The 500 mM CPX aliquots were further 
diluted 1:1250 in HG DMEM to form a 400 μM (50x) stock solution for 
drug treatment. Desferrioxamine mesylate (DFO) was dissolved 
directly in HG DMEM at a concentration of 10 mM to form a 200x stock 
solution. All stocks were then sterilized by filtration through sterile 0.2 
micron filters. 
Treatment media (± PHIs, ± osteogenic induction supplements) for 
assays were then prepared by mixing HG DMEM with appropriate 
volumes of PHI stocks and other supplements (FBS, penicillin, 
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streptomycin, L-ascorbic acid magnesium phosphate, dexamethasone,
  and beta-glycerophosphate). The final PHI concentrations for 
cell culture were 10 mM for PDCA, 8 μM for CPX, and 50 μM for DFO. 
5.3.3. Preparation of fixatives 
For formaldehyde fixation, 4% formaldehyde in phosphate buffered 
saline (PBS) was prepared by reconstituting 10 ml of 16% methanol-
free formaldehyde in de-ionized water from ampoules (Thermo 
Scientific, Lafayette, CO, USA) with 4 ml of 10x PBS (1st Base, 
Singapore) and 26 ml Milli-Q water. The 4% formaldehyde in PBS 
solution was then stored at –20°C. For methanol fixation, analytical 
grade methanol (Fisher Chemicals, Pittsburgh, PA, USA) was stored at 
–20°C and used cold. 
5.3.4. Cytotoxicity assay 
To assess whether the PHIs were cytotoxic to NHOsts at the 
concentrations used, NHOsts were seeded at a density of 10,000 cells 
per well in a 48-well plate, allowed to attach overnight, then treated for 
24 hours in osteoblast assay medium ± PHIs and ± osteogenic 
induction supplements. Subsequently, cell culture media samples were 
harvested for immediate analysis using Invitrogen’s Vybrant cytotoxicity 
assay, which measures the leakage of the cytosolic enzyme glucose 6-
phosphate dehydrogenase (G6PD) from compromised cells. 
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Fluorescence measurements were made using a FLUOstar Optima 
plate reader (BMG Labtech, Durham, NC, USA). 
5.3.5. Assessing PHIs’ effects on cellular HIF-1α levels 
NHOsts were seeded at a density of 1000 cells per well in a 48-well 
plate and allowed to attach overnight. Subsequently, they were treated 
for 4 hours with osteoblast assay medium ± PHIs (without osteogenic 
induction supplements), then immediately rinsed with PBS, fixed in 4% 
formaldehyde in PBS for 15 min, and rinsed 3x with PBS to remove 
excess formaldehyde. The fixed cells were then blocked with 3% BSA 
and immunostained for HIF-1α using a mouse monoclonal antibody 
against HIF-1α (BD Biosciences, San Jose, CA, #610959) and Alexa 
594 fluorophore-conjugated goat anti-mouse secondary antibodies 
(Invitrogen). 
5.3.6. Durations of PHI treatment 
To evaluate PHIs’ effects on collagen I production by NHOsts, NHOsts 
were seeded at a density of 2,000 cells per well in 24-well plates. A low 
cell density of 2,000 cells per well was used because the NHOsts 
multiply extremely rapidly under osteogenic induction, such that there 
would be a possibility of the cell layer tearing and peeling if a higher 
starting cell density was used. The cells were allowed to attach 
overnight, after which they were treated for 1 to 4 weeks in osteoblast 
medium ± PHIs and ± osteogenic induction supplements. 
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In an alternative set-up, NHOsts were similarly seeded at 2,000 cells 
per well in 24-well plates, allowed to attach overnight, then treated for 1 
week with osteoblast medium ± PHIs and ± osteogenic induction 
supplements. Subsequently, the osteoblasts were treated for a further 
3 weeks with osteoblast medium ± osteogenic induction supplements, 
but without PHIs. 
5.3.7. Analysis of VEGF secretion 
To assess PHIs’ effects on VEGF secretion, medium samples from the 
first 3 days of treatment (± PHIs and ± osteogenic induction) were 
harvested and analyzed using a Quantikine VEGF ELISA kit (R&D 
Systems, Minneapolis, MN, USA) according to the manufacturer’s 
instructions. Optical density measurements were made using an Infinite 
M200 plate reader (Tecan). 
5.3.8. Assessing PHIs’ effects on collagen secretion 
Culture medium samples from the first week of treatment (± PHIs, ± 
osteogenic induction) were harvested, and 150 μl was aliquoted from 
each sample for analysis of secreted collagen. The aliquots were first  
digested with 15 µl of 1 mg/ml pepsin from porcine gastric mucosa 
(Roche Diagnostics Asia Pacific, Singapore) in 1N hydrochloric acid 
(Sigma-Aldrich) for 2 hours at room temperature with shaking to 
remove non-collagenous proteins, after which the digestion was 
stopped by neutralizing the acid with 18 µl of 1N sodium hydroxide 
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(Sigma-Aldrich). The digested samples were analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under 
non-reducing conditions using in-house 3% stacking/5% resolving gels. 
Type I collagen (Koken, Tokyo, Japan) was used as standards. Protein 
bands were stained using the SilverQuest silver staining kit (Invitrogen) 
according to the manufacturer’s instructions, and densitometric 
analysis of the stained bands was performed using a GS-800 
Calibrated Densitometer (Bio-Rad, Hercules, CA, USA) and Quantity 
One image analysis software (Bio-Rad). 
5.3.9. Immunocytochemical staining for type I collagen and 
osterix 
To assess PHIs effects on collagen I deposition and osterix protein 
levels, NHOsts treated for 1 to 4 weeks (± PHIs, ± osteogenic 
induction) were rinsed with PBS and fixed in pre-chilled methanol at 
−20°C for 5 min. The methanol was then removed, and the cell layers 
were allowed to dry thoroughly. The fixed cells were then blocked with 
3% bovine serum albumin (BSA) and immunostained for type I 
collagen and osterix using a mouse monoclonal antibody against 
collagen I (Sigma-Aldrich, C2456) and a rabbit polyclonal antibody 
against osterix (Abcam, Cambridge, MA, USA, ab22552), and Alexa 
594 and 488 fluorophore-conjugated secondary antibodies against 




5.3.10. Alizarin red staining 
Alizarin red staining was performed to visualize mineralization by the 
osteoblasts. Alizarin red staining solution was prepared by dissolving 
2g of Alizarin red in 100 ml of Milli-Q water. The pH of the Alizarin red 
solution was then adjusted to 4.1 using 0.5% w/v ammonium 
hydroxide. 
NHOsts treated for 4 weeks (± PHIs, ± osteogenic induction) were 
rinsed three times with PBS, then fixed in 4% formaldehyde in PBS for 
15 min and stained by incubating with Alizarin Red staining solution for 
5 min. Subsequently, excess dye was removed by repeatedly rinsing 
the fixed cells with Milli-Q water until no further run-off of the dye could 
be observed. Excess water was then removed, and the plates were air-
dried, then viewed under Brightfield on an Olympus IX31 microscope 
(Tokyo, Japan). 
5.3.11. Statistical analysis 
Data are presented as mean ± standard error. The statistical 
signiﬁcance between groups was determined by Student’s t-test using 
a two-tailed distribution with unequal variance. Differences were 





5.4.1. PHIs stabilize HIF-1α in osteoblasts 
To check whether the PHIs could stabilize HIF-1α at the dosages we 
used, we treated osteoblasts with PHIs for 4 hours, then 
immunostained for HIF-1α (Fig. 5.1). These dosages had been chosen 
based on previous HIF-1α stabilization studies performed in fibroblasts, 
and the 4 hour time-point for observation was based on previous 
studies showing that HIF-1α levels peaked at approximately 4 hours 
after the beginning of PHI treatment. [97] 
 
Fig. 5.1. HIF-1α immunostaining in osteoblasts treated for 4 hours with the PHIs. Cell 
nuclei are counterstained with DAPI. Scale bar = 100 μm. 
Results showed substantial HIF-1α staining in the treated cells, while 
HIF-1α levels in untreated controls were too low to be detected, 
confirming that the PHIs could stabilize HIF-1α in osteoblasts at the 
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dosages we used. The staining is localized mainly to the DAPI-stained 
cell nuclei, as is typical of transcription factors. 
5.4.2. PHIs stimulate VEGF secretion by osteoblasts 
As reviewed in previous chapters, VEGF is a direct target of HIF-1 and 
an important cytokine for both angiogenesis and autocrine signaling in 
osteoblasts. To assess whether PHIs can stimulate VEGF secretion by 
osteoblasts, medium from the first 3 days of treatment with PHIs (± 
osteogenic induction) was analyzed by ELISA (Fig. 5.2). 
Interestingly, different results were obtained in non-induced osteoblasts 
and induced osteoblasts. In the non-induced conditions, osteoblasts 
treated with 50 μM DFO secreted far more VEGF than untreated 
controls (approximately double), but cells treated with 10 mM PDCA 
and 8 μM CPX secreted approximately the same amounts of VEGF as 
the controls. In the induced condition, osteoblasts secreted less VEGF 
overall compared to non-induced osteoblasts, but significant 
differences were observed between PHI-treated cells and untreated 
controls. Cells treated with 50 μM DFO secreted the most VEGF of all 
(~13 fold compared to no PHI controls), while cells treated with 8 μM 





Fig. 5.2. Analysis of secreted VEGF in culture medium samples from osteoblasts 
treated for 3 days with PHIs (± osteogenic induction). 
In terms of VEGF secretion, 50 μM DFO appears to be the most potent 
condition in both non-induced and induced groups, despite the fact that 
PDCA stabilized HIF-1α more strongly, as shown in the HIF-1α 
immunostaining in Fig. 5.1. Reasons for this discrepancy are unclear, 
although it may be due to differences in pharmacokinetics. 
Osteogenic induction dramatically decreased the secretion of VEGF by 
osteoblasts. Comparing the non-induced osteoblasts and the induced 
osteoblasts from the “no PHI” conditions, it can be seen that non-
induced cells secreted ~10x more VEGF than the induced cells. This 
may be because certain components of the osteogenic induction 
cocktail (e.g. dexamethasone) suppress VEGF secretion. Indeed, 
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dexamethasone has been shown in studies to inhibit VEGF production 
in other cell types, possibly via signal transducer and activator of 
transcription 3 (STAT3). [146, 147] 
5.4.3. PHIs reduce collagen production by osteoblasts 
PHIs’ ability inhibit collagen P4H and thereby reduce collagen 
production has been reviewed thoroughly in previous chapters. We 
therefore evaluated PHIs’ effects on collagen secretion and deposition.  
To compare the amounts of secreted collagen, medium from the first 3 
days of treatment with PHIs (± osteogenic induction) was digested with 
pepsin to remove non-collagenous proteins, and the remaining 
collagen was resolved by SDS-PAGE and silver stained (Figs. 5.3a 
and 5.3b). The positions of the resultant bands in the samples matched 
the α1 and α2 bands of the collagen I standards, confirming that 
collagen I was the predominant type of collagen produced. Extremely 
faint bands belonging to another type of collagen were also visible in 
lanes 2 and 3 of the gel in (b), indicating that a different type of 
collagen was also synthesized by the cells, but in far lower quantities. 
Quantitative comparisons were carried out by performing densitometry 
on the stained α1 and α2 bands. Results were normalized to the no 
PHI, non-induced controls (“no PHI, -i”) in each gel and plotted (Fig. 
5.3c). Results showed all 3 PHIs reduced collagen secretion at their 
respective dosages. 10 mM PDCA decreased collagen secretion by 
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about 25% in both non-induced and induced groups, and 8 μM CPX 
and 50 μM DFO decreased collagen by around 50 to 75%. 
 
Fig. 5.3. Analysis of secreted collagen in culture medium samples from PHI-treated 
osteoblasts (± osteogenic induction). (a, b) Silver stained SDS-PAGE gels showing 
prominent collagen I bands. (c) Graph comparing the summed densitometry 
measurements of both the α1 and α2 bands in each sample, normalized to the no 
PHI, non-induced (-i) controls in each gel (lane 3 in (a) and lane 1 in (b)). 
In addition to secreted collagen, we also examined PHIs’ effects on the 
amount of collagen deposited on the culture surface by osteoblasts, by 




Fig. 5.4. Immunostaining for type I collagen deposited by osteoblasts after 1 week of 
treatment with PHIs (± osteogenic induction). Cell nuclei are counterstained with 
DAPI. Scale bar = 500 μm. 
Results showed that the PHIs greatly reduced collagen deposition as 
well, corroborating with the earlier collagen secretion data. These 
results suggest that all three PHIs inhibit collagen P4H, and this 
suppression of collagen production may have an impact on subsequent 
osteogenic differentiation and mineralization, as it is known that 
osteoblasts use the extracellular matrix as a scaffold for mineral 
deposition. [145]  
5.4.4. PHIs increase osterix protein levels in osteoblasts 
As reviewed in the previous chapter, osterix is a transcription factor 
that is necessary for osteoblast differentiation and is a direct 
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transcriptional target of HIF-1. We therefore explored the effects of 
PHIs on osterix protein levels in osteoblasts, by immunostaining for 
osterix in osteoblasts treated for 1 week with PHIs (Fig. 5.5).  
 
Fig. 5.5. Osterix immunostaining in osteoblasts treated for 1 week with PHIs (± 
osteogenic induction). Scale bar = 100 μm. 
As shown in Fig. 5.5, osterix immunostaining co-localized with the 
DAPI stained nuclei, as is typical of transcription factors. In PHI-treated 
conditions, the levels of osterix protein were visibly elevated, 
suggesting that the PHIs upregulated osterix via HIF-1. Unexpectedly, 




Immunostaining of osterix was also performed on osteoblasts treated 
for 2 weeks with PHIs (± osteogenic induction), and results showed 
that osterix levels remained elevated in PHI-treated cells (Fig. 5.6). 
 
Fig. 5.6. Osterix immunostaining in osteoblasts treated for 2 weeks with PHIs (± 
osteogenic induction). Only the controls and the PDCA and CPX-treated cells are 
shown because the DFO-treated cells had almost completely died by week 2 of 
treatment with PHIs. Scale bar = 500 μm. 
In the CPX and DFO-treated groups, cell numbers were visibly lower 
than in the “no PHI” controls, as many cells in those wells had begun to 





5.4.5. Effects of PHI-treatment on cell attachment 
Phase contrast microscopy was performed every week to monitor the 
proliferation and morphology of the cells throughout the 4-week PHI 
treatment process (Figs. 5.7 and 5.8). 
 
Fig. 5.7. Phase contrast microscopy photos taken of osteoblasts treated with PHIs for 





Fig. 5.8. Phase contrast microscopy photos taken of osteoblasts treated with PHIs for 
4 weeks (+ osteogenic induction). Scale bar = 500 μm. 
As shown in the phase contrast photographs, cells in all groups 
proliferated rapidly during the first week of treatment, and there were 
no major differences in cell density between the PHI-treated groups 
and the “no PHI” controls at the end of week 1 (second row in Figs. 5.7 
and 5.8). However, by the end of week 2, significant numbers of cells in 
the CPX and DFO-treated groups began to detach from the well and 
form clumps (third row in each figure), and by the end of week 3, there 
were far fewer cells left in the CPX and DFO-treated groups than there 
were at the end of week 1, as indicated by large swaths of empty 
spaces in the wells. 
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Osteoblasts which were not treated with PHIs reached extreme 
hyperconfluency by the end of week 3, with and without osteogenic 
induction. In non-induced group, the untreated (“no PHI -i”) osteoblasts 
formed multiple overlapping layers (Fig. 5.7), while in induced wells 
(“no PHI +i”), the osteoblasts were beginning to clump, and holes were 
beginning to form in the cell layer where osteoblasts had detached (Fig. 
5.8). The clumping of cells and formation of holes in the cell layer 
indicate that the contractile forces exerted by the cells on each other 
had exceeded the attachment forces between the osteoblasts and the 
culture surface. By the end of week 4, the non-induced “no PHI” 
osteoblasts were still hyperconfluent but attached (Fig. 5.7), while the 
induced “no PHI” osteoblasts had detached considerably, resulting in a 
morphology similar to the CPX-treated cells at the end of week 2 (Fig. 
5.8). 
Interestingly, the PDCA-treated cells appeared to be relatively 
unaffected by detachment issues. PDCA-treated osteoblasts in the 
non-induced group appeared to proliferate more slowly than the 
untreated controls and did not reach the state of hyperconfluency 
observed in the untreated controls (Fig. 5.7). This is consistent with 
PDCA’s known anti-proliferative effects discussed in chapter 2 and in 
prior literature. [95] PDCA-treated cells which were induced remained 
properly attached at the end of week 3, and only began to form clusters 




5.4.6. Cytotoxicity assay 
To assess whether the PHIs were toxic to osteoblasts at the dosages 
used in this study, we performed a cytotoxicity test on culture medium 
harvested from osteoblasts treated for 24 hours with PHIs (± 
osteogenic induction), using Invitrogen’s Vybrant cytotoxicity assay (Fig. 
5.9). The assay measures leakage of the cytosolic enzyme G6PD from 
compromised cells, and thus a higher fluorescence intensity indicates a 
higher percentage of compromised cells. Cells which were completely 
lysed using the lysis buffer provided in the assay kit served as the 
positive control.  
 
Fig. 5.9. Results of the cytotoxicity assay, expressed as % fluorescence intensity vs. 




As shown in Fig. 5.9, PHI-treated cells did not appear to be any more 
compromised than untreated cells. Interestingly, PDCA-treated cells 
were in fact substantially less compromised than untreated controls in 
both the non-induced and induced groups, suggesting a possible 
cytoprotective effect. This is consistent with observations presented in 
the previous section showing that PDCA-treated cells remained firmly 
attached to the culture surface in week 4 of osteogenic induction, even 
when control cells had begun to detach. 
Phase contrast photographs presented in the previous section (Figs. 
5.7 and 5.8) had shown that continuous CPX and DFO treatment 
caused osteoblasts to begin detaching in week 2 of treatment. This 
detachment does not appear to be brought on by immediate 
cytotoxicity, as: (1) cytotoxicity assay results showed that CPX and 
DFO did not compromise the cells any more than the controls, and (2) 
osteoblasts treated with CPX and DFO proliferated well and exhibited 
normal morphologies during the first week. However, it is possible that 
CPX and DFO have latent cytotoxic effects on osteoblasts, possibly 
stemming from their shared ability to chelate iron, since iron is needed 
for the normal functioning of numerous enzymes besides prolyl 
hydroxylases. [66, 148] 
By contrast, PDCA does not inhibit prolyl hydroxylases by iron 
chelation, but by acting as an analog of 2-oxoglutarate. [149] Therefore, 
while PDCA can inhibit other 2-oxoglutarate-dependent enzymes such 
as FIH, it is unlikely to affect iron-dependent enzymes that do not use 
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2-oxoglutarate. This may be a reason why PDCA-treated osteoblasts 
fared better than their CPX and DFO-treated counterparts. 
5.4.7. PHIs’ effects on mineralization 
As reviewed in the previous chapter, HIF-1 and its transcriptional target 
VEGF are both involved in osteogenesis. Our results presented in 
previous sections have shown that the PHIs we used were able to 
stabilize HIF-1α, stimulate VEGF secretion and increase osterix levels 
in osteoblasts. At the same time, the PHIs also decreased the 
secretion and deposition collagen I by osteoblasts. All of these effects 
may affect osteoblasts’ ability to mineralize, both positively and 
negatively. We therefore assessed the effects of PHI-treatment on 
mineralization by performing Alizarin Red staining at week 4 of 
osteogenic induction (Fig. 4.10). 
As discussed in previous sections, we initially treated osteoblasts for 4 
weeks with PHIs, with and without osteogenic induction, and observed 
that cells in the CPX and DFO groups started detaching in week 2 of 
PHI treatment, and to the extent that there were hardly any cells left in 
those wells by week 4 (Fig. 5.10a). We therefore repeated the 
experiment and reduced the PHI treatment duration to just the first 




Fig. 5.10. Alizarin Red staining at week 4. (a) Osteoblasts were treated with PHIs ± 
osteogenic induction for 4 weeks. (b) Osteoblasts were treated ± osteogenic induction 
supplements for 4 weeks and PHIs during the first week only. Scale bar = 1 mm. 
Comparing cell numbers in Fig. 5.10a with Fig. 5.10b (4-week PHI 
treatment vs. 1-week PHI treatment), it can be seen that reducing the 
CPX and DFO treatment to just the first week increased the number of 
cells remaining at the end of the 4-week experiment, but did not 
completely abrogate cell detachment. This suggests that CPX and 
DFO treatment in the first week had lasting effects, which persisted 
long after PHI treatment had ended. 
As shown in Fig. 5.10 above, treatment with different PHIs and for 
different durations had distinctly different effects on mineralization. 
Among non-induced conditions, no Alizarin Red staining was observed, 
demonstrating that none of the PHIs could induce mineralization in the 
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absence of osteogenic induction supplements. This is not surprising as 
beta-glycerophosphate, a key osteogenic induction supplement that 
serves as a source of phosphate ions for the formation of mineral 
deposits in vitro, was absent from the medium of non-induced groups. 
Among induced groups, the untreated “no PHI” controls exhibited 
strong Alizarin Red staining. 4-week treatment with 10 mM PDCA for 4 
weeks resulted in no Alizarin Red staining, but when the PDCA 
treatment was limited to just the first week, the Alizarin Red staining 
became comparable to untreated controls. 
CPX treatment for 4 weeks resulted in substantial Alizarin Red staining, 
despite the fact that much of the cells had detached by that point. 
Limiting CPX treatment to just the first week greatly improved the 
number of cells remaining attached at the end of week 4, but 
unexpectedly resulted in no Alizarin Red staining. DFO treatment for 4 
weeks or just the first week both resulted in weak Alizarin Red staining. 
Although the effects on mineralization varied greatly across different 
PHIs and durations of treatment, it can be seen that none of our PHI-
treatment conditions increase mineralization relative to controls. Only 
one condition (1-week PDCA treatment) resulted in Alizarin Red 
staining comparable to controls, and all other PHI-treatment conditions 
decreased mineralization. This decrease in mineralization may be due 
to the PHIs’ inhibition of collagen secretion and deposition 
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demonstrated in previous sections, as collagen is known to act a 
scaffold for the deposition of hydroxyapatite. [145] 
In addition, cell detachment issues in the CPX and DFO-treated groups 
also likely contributed to the decreased mineralization observed in 
those groups. However, reducing CPX treatment to just the first week 
unexpectedly resulted in less mineralization than a 4-week CPX 
treatment despite having increased the number of cells remaining. It is 
thus likely that there are other mechanisms that PHIs influence 
mineralization, besides those mentioned above. 
5.5. Discussion 
As shown in the results presented in the previous sections, all the PHIs 
we tested (10 mM PDCA, 8 μM CPX, and 50 μM DFO) stabilized HIF-
1α in osteoblasts and increased their expression of VEGF and osterix, 
both known transcriptional targets of HIF-1. As reviewed in the 
previous chapter, VEGF is important for both angiogenesis and 
osteogenesis. The ability of PHIs to stimulate VEGF secretion is 
therefore highly desirable in the application of bone regeneration. 
The implications of PHIs’ ability to increase osterix levels, however, are 
not as clear. It is known that osterix is necessary for endochondral 
ossification and is involved in the regulation of degradation of 
chondrogenic matrices and of calcification. [135] However, the scope of 
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osterix’s function has yet to be fully elucidated, and thus it is difficult to 
predict the implications of PHIs’ ability to elevate osterix protein levels. 
Results from our collagen studies showed that the same PHIs strongly 
suppressed collagen secretion and deposition, confirming that the PHIs 
also inhibit collagen P4H in addition to HIF-PHDs. The ability of PHIs to 
inhibit collagen production may be detrimental to bone regeneration, as 
collagen is an important component of bone. [145] Indeed, our Alizarin 
Red staining results showed that PHIs generally reduced mineralization, 
although limiting PDCA treatment to just the first week restored 
mineralization to levels comparable to untreated controls, suggesting 
that collagen production can recover after cessation of PHI treatment. 
However, it is important to note that the extent of PHIs’ effects on 
collagen production may be less pronounced in vivo, as drugs present 
in a tissue are constantly being removed by the circulation system and 
renal clearance. Indeed, Shen et al. and Wan et al.’s studies in mouse 
models showed that bone and callus formation increased after five 
injections with DFO, given on alternate days. [84, 101] Their 
observations suggest that DFO’s effects on collagen production, at the 
rates and dosages used in their studies, were not strong enough to be 
detrimental to bone and callus formation. 
With respect to effects on cell viability, our cytotoxicity assay results 
showed that the PHIs were not immediately cytotoxic to osteoblasts. 
However, prolonged treatment with CPX and DFO caused osteoblasts 
to start detaching, beginning in week 2, even though they had 
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appeared normal and proliferated rapidly during week 1. Limiting the 
CPX and DFO treatment periods to just the first week reduced the 
percentage of cells which detached, but did not completely abrogate 
cell detachment. By contrast, PDCA treated cells remained well-
attached throughout the 4-week assay. These results suggest that the 
detachment of CPX and DFO-treated osteoblasts was likely not caused 
by effects on HIF-PHDs and collagen P4H, since all 3 drugs inhibited 
these enzymes; instead, the cell detachment is more likely caused by 
CPX and DFO’s shared ability to chelate iron, which would affect all 
enzymes that require iron to function. It would be unsurprising if 
prolonged iron chelation reduces cell viability, as it has long been 
known that iron is a co-factor in numerous enzymes aside from prolyl 
hydroxylases. [148] These include respiratory enzymes such as 
cytochrome oxidase and NADH ubiquinone reductase, as well as other 
metabolic enzymes such as ribonucleotide reductase, which is 
necessary for DNA synthesis, and the entire cytochrome P450 
superfamily. [148] Therefore, as iron chelators, CPX and DFO are likely 
to inhibit these enzymes and cause undesired impairment of various 
cellular processes. Indeed, CPX has been explored as a potential anti-
cancer agent based on its ability to kill various types of leukemia and 
myeloma cells via iron chelation. [150] 
Taken together, our preliminary results suggest that a short treatment 
(of 1 week or less) with PDCA may be preferable for bone regeneration 
applications, due to its ability to stimulate VEGF production without 
negatively affecting cell viability and mineralization, although in vivo 
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testing in appropriate fracture models are necessary to adequately 
assess PDCA’s utility in bone healing and determine suitable dosages 
and durations of treatment. 
5.6. Conclusion 
Our preliminary results suggest that PHIs may be useful for bone 
regeneration applications, but the type of PHI used and the duration of 
PHI treatment are both critical factors that determine actual therapeutic 
potential. In addition, while in vitro experiments are useful for assessing 
PHIs’ signaling effects on osteoblasts, they have many constraints that 
limit their ability to predict actual therapeutic potential, such as the lack 
of a circulation and an immune system. Therefore, in vivo experiments 
are necessary to accurately evaluate PHIs’ therapeutic utility in bone 
regeneration applications. It would also be important to test out multiple 
PHIs, at different dosages and for different durations of treatment, 
during these in vivo studies. 
In addition, PHIs that are iron chelators may have many adverse 
effects stemming from their inhibition of other important iron-dependent 
enzymes, and thus they should be used with caution. Although CPX 
and DFO are both approved for use in humans by the US Food and 
Drug Administration (as a topical anti-fungal agent and as an iron 
chelator, respectively), their utility in bone regeneration will have to be 
carefully evaluated in in vivo and clinical studies, and dosages and 
treatment durations fine-tuned to minimize adverse effects. 
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Lastly, since PHIs’ effects on collagen P4H may interfere with their 
utility in bone regeneration, it would be ideal if specific PHIs targeting 
only HIF-PHDs and FIH but not collagen P4H can be developed. 
However, due to the similarities and differences between HIF-PHDs, 
FIH and collagen P4H, the development of a drug that can inhibit both 




Chapter 6  




6.1. Summary of key findings 
In this PhD project, we developed a novel method to incorporate the 
PHI PDCA into amine-containing scaffolds via amide bonds, using a 
gelatin sponge (Gelfoam) as a test scaffold. We showed that PDCA 
incorporated at various concentrations into the scaffold (up to 15% 
w/w) could stabilize HIF-1α in infiltrating cells, stimulate VEGF 
production, and increase vascular infiltration when implanted in a rat 
angiogenesis model. We also showed that the PDCA-incorporated 
gelatin sponges had low cytotoxicity (comparable with controls) and 
supported cell proliferation and infiltration. These results demonstrate 
that the incorporation of the PHI PDCA into scaffolds is a feasible 
approach for improving vascular infiltration. 
We also performed a preliminary study to evaluate the effects of 
various PHIs in osteoblasts, with the aim of assessing their utility in 
improving bone regeneration and fracture healing. Our results showed 
that the PHIs tested (10 mM PDCA, 8 μM CPX, and 50 μM DFO) were 
all able to stabilize HIF-1α and upregulate VEGF and osterix, two HIF-1 
targets important to angiogenesis and osteogenesis. The three PHIs at 
their respective dosages also suppressed collagen secretion and 
deposition. With respect to cell viability, all three PHIs had low initial 
cytotoxicity comparable with controls, and PDCA-treated cells 
remained well-attached throughout the 4-week assays. However, CPX 
and DFO treatment (continuous or limited to the first week) caused a 
substantial proportion of the osteoblasts to begin detaching in week 2 
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of culture, possibly due to their shared ability to chelate iron, which may 
affect multiple iron-dependent enzymes besides prolyl hydroxylases. 
The three PHIs also had different effects on the mineralization of 
osteoblasts, with most PHI treatments resulting in reduced 
mineralization, possibly as a result of effects on collagen production 
and cell viability. Interestingly, while continuous treatment with 10 mM 
PDCA completely abrogated mineralization, limiting the PDCA 
treatment to just the first week of culture restored mineralization to 
levels comparable with controls. These results suggest that: (1) PHIs 
with different mechanisms of action can have very different effects on 
osteoblasts, and (2) while PHIs may benefit bone regeneration by 
upregulating important signaling molecules such as VEGF, they should 
probably not be administered continuously throughout the bone healing 
process. 
6.2. Future work 
6.2.1. Assessing functional vascularization 
In this project, we assessed in vivo vascular infiltration by sectioning 
explants, immunostaining for an endothelial cell marker (RECA-1), and 
quantifying the density of endothelial cells. However, the density of 
endothelial cells is only one parameter of vascular infiltration, and it 
would be useful to assess functional vascularization parameters (e.g. 
vessel perfusion, morphology, and integrity). Evaluating these 
parameters would allow us to conclusively determine whether the 
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vessels resulting from the delivery of PHIs from scaffolds are 
functionally superior to vessels generated by other means (e.g. delivery 
of VEGF).  
Assessment of functional vascularization can be performed by 
perfusing animals with fluorescent agents that label vascular 
endothelium, such as lipophilic dyes (e.g. 1,1'-dioctadecyl-3,3,3',3'-
tetramethyl-indocarbocyanine perchlorate) or lectin conjugated with 
fluorophores (e.g. FITC-lectin). [151, 152] The fluorescently-labeled 
perfused vessels can then be subsequently imaged by sectioning the 
explants and viewing slices under a fluorescence or confocal 
microscope. Perfusion with fluorescent dyes also enables researchers 
to determine vessel integrity (i.e. whether the vessels are leaky). 
However, the volume of perfused tissue which can be imaged at each 
time is constrained by the thickness of the slices. In addition, as the 
explant has to be sectioned, a complete three-dimensional 
reconstruction of the original vasculature is impossible. 
To overcome these limitations, X-ray microcomputed tomography 
(micro-CT) can be used instead to image perfused vasculature. In this 
method, animals are first perfused with an appropriate contrast agent, 
after which the vasculature of the tissue of interest can be visualized by 
micro-CT imaging while the animal is still intact. [153, 154] The 
tomographic data can be processed using a variety of algorithms for 
advanced quantitative analyses, such as generation of a three-
dimensional reconstruction of the vasculature, calculation of the vessel 
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volume, average vessel diameter, and degree of anisotropy. [154] 
Vessels in the three-dimensional reconstruction can also be color-
coded by vessel diameter. [154] 
6.2.2. Applying our findings pertaining to PDCA-Gelfoam 
Soft tissue engineering applications 
As described in the previous section, we have developed a method to 
incorporate a PHI into amine-containing scaffolds and demonstrated its 
feasibility in stimulating vascularization. Our proof-of-concept scaffold, 
PDCA-Gelfoam, was conducive to cell attachment, proliferation, and 
infiltration, and was able to induce vascular infiltration in a dose-
dependent manner. However, as the base material (Gelfoam) is a 
gelatin sponge, the PDCA-Gelfoam scaffolds have relatively low 
mechanical strength and may be suitable mainly for soft tissue 
engineering applications. Studies can thus be performed to assess 
PDCA-Gelfoam’s efficacy in accelerating tissue regeneration in animal 
models for specific applications (e.g. chronic wounds, myocardial 
infarction). 
As our method of incorporating PDCA into scaffolds utilizes PDCA’s 
intrinsic carboxylic acid groups to form amide bonds with amine groups 
in the scaffold, it is compatible with all amine-containing materials. 
These include all protein-based materials, as well as synthetic 
polymers containing amine groups, such as nylon and other 
 113 
 
polyamides. Therefore, depending on the needs of the specific 
application, the material can be switched from Gelfoam to any of these 
other materials to match the needs. 
Combining PDCA-Gelfoam with in vitro pre-vascularization 
In our in vivo study, we explored PDCA-Gelfoam’s ability to stimulate 
vascularization as a standalone material (i.e. without pre-seeding it with 
cells before implantation), and showed that it was effective on its own. 
However, since the incorporated PDCA stimulates vascularization by 
switching on the intrinsic angiogenic programming in infiltrating cells, it 
should also be able to improve in vitro pre-vascularization by similarly 
enhancing the formation of capillary pre-cursors. The incorporation of 
PHIs into scaffolds is thus likely to work synergistically with in vitro pre-
vascularization to further improve vascular infiltration, and we should 
try combining the two techniques in future studies. 
6.2.3. Developing PHI-delivering materials for bone regeneration 
and tissue engineering 
As reviewed in chapter 3, PHIs have many potential applications in 
bone and cartilage regeneration. Although PDCA-Gelfoam exhibited 
excellent compatibility with cells and successfully stimulated 
vascularization in vivo, its lack of mechanical strength makes it 
unsuitable for applications in bone, since a scaffold should ideally have 
mechanical properties that match the tissue in which it is implanted, 
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and bone has important load-bearing functions. [155] Therefore, 
different PHI-delivering scaffolds should be developed for bone tissue 
engineering applications. 
Our preliminary studies in osteoblasts have also shown that different 
PHIs and treatment durations can have very different effects on the 
same cell type. Therefore, it may be preferable to first test out multiple 
PHIs in appropriate animal models to determine the best PHI treatment, 
before designing a PHI-delivering material for a specific application. 
6.3. Conclusions 
In this PhD project, we have developed a simple and cost-effective 
method to incorporate PHIs into amine-containing scaffolds, and 
demonstrated that it is feasible as a strategy for improving vascular 
infiltration. We have also explored the effects of three PHIs on 
osteoblasts, and found that while all the PHIs we tested can switch on 
HIF-1 signaling and decrease collagen production, the type of PHI 
used and the duration of treatment are also important factors 
influencing subsequent osteoblast behavior. 
In conclusion, our results suggest that the use of PHIs is a promising 
approach for inducing vascularization in regenerating tissues. 
Additionally, as different PHIs can have a wide range of effects in 
different tissues, more studies will have to be performed in suitable 
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